🏷

Classifications

Harrison's Part

👪

Inheritance

1

Autosomal recessive inheritance HP:0000007

DEE50 is autosomal recessive, caused by biallelic CAD variants in the homozygous or compound heterozygous state. Reported families include both consanguineous unions and unrelated compound heterozygotes.

Autosomal recessive inheritance Expressivity: VARIABLE

Show evidence (2 references)

PMID:32820246 SUPPORT Human Clinical

"Biallelic CAD variants underlie CAD deficiency"

Establishes biallelic causation and names the salvage route that the treatment exploits.

PMID:38454370 SUPPORT Human Clinical

"Five patients had consanguineous parents, and 12 had a reported family history."

Documents both consanguineous and familial occurrence across the 42-patient literature review, consistent with recessive inheritance.

?

Discussions and Knowledge Gaps

2

By what route does depletion of pyrimidine nucleotides and UDP-sugars produce neuronal injury, seizures and brain atrophy, rather than a uniform proliferation defect?

KNOWLEDGE GAP OPEN gap_pyrimidine_depletion_to_neuronal_injury

Attached to

pathophysiology#Pyrimidine Nucleotide and UDP-Sugar Pool Depletion pathophysiology#Progressive Neuronal Injury and Brain Atrophy

The metabolic lesion is measured directly in patient fibroblasts and the clinical endpoint is well described, but nothing in between is. Proposed routes include impaired glycosylation of neuronal proteins, since UDP-sugar donors are depleted, and impaired nucleic acid synthesis during neuronal differentiation; neither has been demonstrated in neural tissue from an affected individual or a model. The gap matters practically: it is why there is no biomarker of neuronal involvement, and why treatment response is monitored with seizure counts and blood films rather than anything mechanism-specific.

Proposed experiments

Glycosylation and nucleotide status in CAD-deficient neurons

exp_neuronal_glycosylation_in_cad_deficiency

Differentiate neurons from a CAD-deficient patient iPSC line (one already exists) alongside isogenic controls, and measure UDP-sugar pools, protein glycosylation and neurite outgrowth with and without uridine. A glycosylation deficit correcting on uridine would support the glycosylation route; a normal glycan profile with impaired outgrowth would point at the nucleic-acid-synthesis route instead.

Show evidence (1 reference)

PMID:32820246 SUPPORT Human Clinical

"With no biomarker available, the diagnosis relies on genetic testing and functional validation in patient-derived fibroblasts."

The absence of a biomarker is the practical face of this gap — no measured quantity tracks the neuronal arm of the disease.

How much of the neurological damage in CAD deficiency is reversible, and does the answer depend on age at which uridine is started?

KNOWLEDGE GAP OPEN gap_treatment_timing_and_reversibility

Attached to

pathophysiology#Progressive Neuronal Injury and Brain Atrophy

The evidence that timing matters is real but thin: one sibling pair in which the younger sib treated at 5 improved dramatically and the older treated at 14 only modestly. That is a single family, and severity and age are confounded within it — the brother is described as having had a more severe course independently of when he was treated. The question is consequential because it is the argument for newborn screening, which the founding study and the largest series both raise.

Proposed experiments

Age-stratified outcome registry

exp_age_stratified_uridine_response

Pool treated patients across centres and relate response — seizure freedom, developmental trajectory, arrest of atrophy on serial MRI — to age at treatment initiation and to pre-treatment severity separately, so the two can be disentangled. At the current cohort size this needs international pooling rather than a single series.

Show evidence (1 reference)

PMID:33497533 SUPPORT Human Clinical

"Her older brother had a more severe course and only modest response to uridine started at 14 years old."

Classified PARTIAL: the observation is consistent with a timing effect but confounds it with baseline severity, which is exactly the ambiguity the proposed experiment is meant to resolve.

⚙

Pathophysiology

7

Biallelic CAD Loss of Function

CAD is a single 2,225-residue polypeptide that assembles into a roughly 1.5 MDa hexameric particle carrying four catalytic domains in one chain: glutamine amidotransferase, carbamoyl phosphate synthetase II, aspartate transcarbamoylase and dihydroorotase. The covalent fusion of these activities into one particle is unique to animals. Biallelic variants reduce or abolish activity; missense alleles predominate and can act by disrupting oligomerization of a domain rather than by destroying a catalytic site — the feline variant below is a worked example of that route. A hypomorphic allelic class retaining partial activity produces a milder, primarily haematological phenotype.

CAD hgnc:1424

carbamoyl-phosphate synthase (glutamine-hydrolyzing) activity GO:0004088 ↓ DECREASED aspartate carbamoyltransferase activity GO:0004070 ↓ DECREASED dihydroorotase activity GO:0004151 ↓ DECREASED

Experimental models

CRISPR CAD-knockout human cell line CELL LINE A complete CAD knockout reproduces the defining cellular consequence of the human lesion: uridine dependence for survival.

Animal models

CAD-deficient Bengal cat Cat recapitulates The feline variant abolishes CAD function in the same complementation assay used to classify human variants, and the affected kitten had intractable seizures.

Downstream

Impaired De Novo Pyrimidine Biosynthesis Loss of the CAD activities blocks the first three of the six reactions that make UMP.

Show evidence (3 references)

PMID:40251393 SUPPORT Model Organism

"The variant, XP_011279586.1:p.(Ser2015Asn), was predicted to affect the oligomerization of the C-terminal aspartate transcarbamylase (ATCase) domain of CAD."

A worked example of the oligomerization route to loss of function, in which the substitution disrupts domain assembly rather than a catalytic site. Evidence source is MODEL_ORGANISM because the variant is feline.

PMID:34288185 SUPPORT Other

"CAD is a 1.5 MDa particle formed by hexameric association of a 250 kDa protein divided into different enzymatic domains, each catalyzing one of the initial reactions for de novo biosynthesis of pyrimidine nucleotides: glutaminase-dependent Carbamoyl phosphate synthetase, Aspartate..."

Establishes the architecture and the catalytic domains whose loss defines the trigger, and is the source for the glutamine-hydrolyzing (not ammonia-dependent) carbamoyl phosphate synthetase activity bound above.

PMID:34288185 SUPPORT Other

"the covalent linkage of the first enzymatic activities into a multienzymatic CAD particle is unique to animals"

Supports the statement that the multienzyme fusion is animal-specific, which is why a single gene defect removes three sequential activities.

Impaired De Novo Pyrimidine Biosynthesis

With CAD inactive, flux through de novo pyrimidine synthesis fails. Metabolic flux studies in patient fibroblasts show impaired incorporation of aspartate into RNA and DNA by this route. This is the rate-limiting lesion of the disease, and its position matters therapeutically: it lies upstream of the point at which the de novo and salvage routes converge, which is what leaves the disease bypassable.

Dermal fibroblast CL:0002620

'de novo' UMP biosynthetic process GO:0044205 ↓ DECREASED 'de novo' pyrimidine nucleobase biosynthetic process GO:0006207 ↓ DECREASED

Downstream

Pyrimidine Nucleotide and UDP-Sugar Pool Depletion The blocked pathway fails to supply its downstream products.

Show evidence (1 reference)

PMID:25678555 SUPPORT In Vitro

"Metabolic flux studies showed impaired aspartate incorporation into RNA and DNA through the de novo synthesis pathway."

Direct measurement of the blocked flux in cells from an affected individual.

Pyrimidine Nucleotide and UDP-Sugar Pool Depletion

The consequence is not only a nucleic-acid precursor shortage. CTP and UTP fall, and so do nearly all UDP-activated sugars, which are the donor substrates for glycosylation. The original report of the disease framed it as a glycosylation disorder for exactly this reason. Cells that rely on de novo synthesis rather than salvage — proliferating cells such as erythroid precursors, and neurons during development — are the ones that feel it.

Neuron CL:0000540 Erythroid lineage cell CL:0000764

'de novo' UMP biosynthetic process GO:0044205 ↓ DECREASED

Experimental models

Patient-derived dermal fibroblasts PRIMARY CELL CULTURE Direct quantification of the depleted nucleotide and UDP-sugar pools in human patient cells, with uridine rescue.

Downstream

Dyserythropoiesis Erythroid precursors are proliferative and depend on de novo supply.

Progressive Neuronal Injury and Brain Atrophy The developing and mature brain is the other affected compartment. How pool depletion produces neuronal injury specifically is not established — see the gap_pyrimidine_depletion_to_neuronal_injury discussion.

Show evidence (1 reference)

PMID:25678555 SUPPORT In Vitro

"CTP, UTP and nearly all UDP-activated sugars that serve as donors for glycosylation were decreased. Uridine supplementation rescued these abnormalities, suggesting a potential therapy for this new glycosylation disorder."

Establishes both arms of the depletion — nucleotide and glycosylation donor — and that uridine corrects them, which is the mechanistic basis of the treatment node below.

Dyserythropoiesis

The haematological arm is a dyserythropoietic anaemia with a strikingly abnormal blood film — anisopoikilocytosis, with target cells and poikilocytes described. It is one of the few features that can point at the diagnosis before sequencing, and it resolves on uridine. In the hypomorphic allelic class it can be the presenting and near-only feature.

Erythroid lineage cell CL:0000764

Show evidence (2 references)

PMID:28007989 SUPPORT Human Clinical

"Exome sequencing in three families identified biallelic CAD mutations in four children with global developmental delay, epileptic encephalopathy, and anaemia with anisopoikilocytosis."

The founding description of the haematological phenotype alongside the neurological one.

PMID:28007989 SUPPORT Human Clinical

"Blood smears normalized and anaemia resolved."

Establishes that this node is reversible on uridine, which is what makes it usable as a treatment-response readout.

Progressive Neuronal Injury and Brain Atrophy

Neuroimaging shows brain atrophy in most of the patients who have an abnormal MRI, involving the whole brain or the cerebellum, with delayed myelination and hydrocephalus reported less often. The atrophy is progressive if untreated, and at least one sibling pair showed that uridine can arrest it. This entry does not declare conformance to cerebellar_purkinje_degeneration: cerebellar atrophy is an imaging finding here, and no Purkinje-cell-specific lesion has been demonstrated in CAD deficiency.

Neuron CL:0000540

Downstream

Epileptic Encephalopathy Ongoing neuronal injury accompanies the seizure disorder and the loss of developmental skills.

Show evidence (2 references)

PMID:38454370 SUPPORT Human Clinical

"Our study demonstrated that one-third of the reviewed cases had MRI abnormalities, with delayed myelination and brain atrophy being the main manifestations in infants and older children, respectively. The cerebral and/or cerebellar atrophy gradually progressed after 3.5 years of age."

Gives the imaging picture and its age dependence, and states that the atrophy is progressive rather than static.

PMID:33497533 SUPPORT Human Clinical

"uridine started at age 5 resulted in dramatic improvements in seizure control and development, cessation of cerebellar atrophy, and resolution of hematological abnormalities"

Shows the atrophy is an active, arrestable process rather than a fixed developmental malformation.

Epileptic Encephalopathy

The clinical endpoint is an early-onset, drug-refractory epileptic encephalopathy with recurrent status epilepticus and loss of acquired skills, on a background of developmental delay. Most patients need multiple antiseizure medicines and remain refractory on them. This entry does not declare conformance to epilepsy_excitation_inhibition_imbalance: no excitation-inhibition measurement exists in CAD deficiency, and asserting that module's mechanism would substitute a plausible route for an evidenced one.

Show evidence (2 references)

PMID:32820246 SUPPORT Human Clinical

"Our study confirms CAD deficiency as a progressive EIEE with recurrent status epilepticus, loss of skills, and dyserythropoietic anemia."

Characterizes the endpoint syndrome in a 20-patient series.

PMID:38454370 SUPPORT Human Clinical

"Twenty cases had drug-refractory epilepsy, fourteen had SE, and one had a history of temporal lobectomy and ventriculoperitoneal shunt surgery."

Quantifies refractoriness and status epilepticus in the pooled cohort.

Intact Uridine Salvage Pathway

This node is what the disease is bypassable through, not a lesion. Pyrimidines can be recycled from uridine by a route that does not use CAD and enters the pathway downstream of the block, so supplying uridine restores the depleted pools without repairing the enzyme. It is curated as a node so the treatment below can point at it. The contrast with DTYMK deficiency is instructive and is drawn out in that entry: DTYMK sits downstream of where de novo and salvage converge, so the same trick does not work there.

pyrimidine nucleoside salvage GO:0043097

Show evidence (2 references)

PMID:28007989 SUPPORT Human Clinical

"CAD encodes a multifunctional enzyme involved in de novo pyrimidine biosynthesis. Alternatively, pyrimidines can be recycled from uridine."

States the existence of the CAD-independent route that the therapy uses.

PMID:32820246 SUPPORT Human Clinical

"an error of pyrimidine de novo biosynthesis amenable to treatment via the uridine salvage pathway"

Names the salvage pathway as the treatment route, which is the role this node plays in the pathograph.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

17

Blood 2

Anemia FREQUENT HP:0001903

Show evidence (1 reference)

PMID:38454370 SUPPORT Human Clinical

"The clinical features of the 42 patients included developmental delay or regression (95%), epilepsy (73%), anaemia (71%), extrapyramidal symptoms (33%), dysphagia (23%), hypotonia (14%), and strabismus (7%)"

Supplies the 71% figure and the denominator behind the FREQUENT band.

Macrocytic anemia HP:0001972

Show evidence (1 reference)

PMID:37984840 SUPPORT Human Clinical

"We present a patient with macrocytic anaemia, elevated haemoglobin-A2 levels, anisocytosis, poikilocytosis and target cells in the blood smear, and mild developmental delay."

Documents the milder, haematology-dominant end of the allelic spectrum.

Digestive 1

Dysphagia OCCASIONAL HP:0002015

Show evidence (1 reference)

PMID:38454370 SUPPORT Human Clinical

"The clinical features of the 42 patients included developmental delay or regression (95%), epilepsy (73%), anaemia (71%), extrapyramidal symptoms (33%), dysphagia (23%), hypotonia (14%), and strabismus (7%)"

Supplies the 23% figure and denominator behind the OCCASIONAL band.

Eye 1

Strabismus OCCASIONAL HP:0000486

Show evidence (1 reference)

PMID:38454370 SUPPORT Human Clinical

"dysphagia (23%), hypotonia (14%), and strabismus (7%)"

Supplies the 7% figure against the 42-patient denominator behind the OCCASIONAL band.

Musculoskeletal 1

Hypotonia OCCASIONAL HP:0001252

Show evidence (1 reference)

PMID:38454370 SUPPORT Human Clinical

"dysphagia (23%), hypotonia (14%), and strabismus (7%)"

Supplies the 14% figure behind the OCCASIONAL band.

Nervous System 6

Global developmental delay VERY_FREQUENT HP:0001263

Show evidence (1 reference)

PMID:38454370 SUPPORT Human Clinical

"The clinical features of the 42 patients included developmental delay or regression (95%), epilepsy (73%), anaemia (71%), extrapyramidal symptoms (33%), dysphagia (23%), hypotonia (14%), and strabismus (7%)"

Gives the 95% figure with an explicit 42-patient denominator, which is what the VERY_FREQUENT band rests on.

Developmental regression HP:0002376

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:32820246 SUPPORT Human Clinical

"Our study confirms CAD deficiency as a progressive EIEE with recurrent status epilepticus, loss of skills, and dyserythropoietic anemia."

Names loss of skills as a confirmed feature of the disorder.

Ataxia FREQUENT HP:0001251

Show evidence (2 references)

PMID:38454370 SUPPORT Human Clinical

"highlights the high incidence of extrapyramidal symptoms in approximately one-third of the cases"

Puts the extrapyramidal category, of which ataxia is the commonest component, at about one-third of patients — the basis for the FREQUENT band.

PMID:32820246 SUPPORT Human Clinical

"We further refine the phenotype by reporting a movement disorder as a frequent feature"

Independent confirmation that the movement disorder is frequent rather than incidental.

Tremor HP:0001337

Show evidence (1 reference)

PMID:38454370 SUPPORT Human Clinical

"Some manifestations, such as extrapyramidal symptoms, dysphagia, and hypotonia, have been underappreciated in previous reports."

Classified PARTIAL: tremor is one component of the extrapyramidal category this sentence covers. The per-symptom tremor count appears only in the review's summary table, which does not extract as quotable prose.

Cerebral atrophy HP:0002059

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:38454370 SUPPORT Human Clinical

"Our study demonstrated that one-third of the reviewed cases had MRI abnormalities, with delayed myelination and brain atrophy being the main manifestations in infants and older children, respectively. The cerebral and/or cerebellar atrophy gradually progressed after 3.5 years of age."

States brain atrophy as a main imaging manifestation in older children and records that it progresses, which the clinical_course qualifier captures.

Cerebellar atrophy HP:0001272

Course: PROGRESSIVE

Show evidence (2 references)

PMID:38454370 SUPPORT Human Clinical

"Our study demonstrated that one-third of the reviewed cases had MRI abnormalities, with delayed myelination and brain atrophy being the main manifestations in infants and older children, respectively. The cerebral and/or cerebellar atrophy gradually progressed after 3.5 years of age."

Records cerebellar atrophy alongside cerebral atrophy and states that it progresses, which is what the clinical_course qualifier asserts.

PMID:33497533 SUPPORT Human Clinical

"We report two siblings with intractable epilepsy, developmental regression, and progressive cerebellar atrophy due to biallelic variants in the gene CAD."

Documents the progressive character that the clinical_course qualifier records.

Other 6

Epileptic encephalopathy FREQUENT HP:0200134

Show evidence (2 references)

PMID:38454370 SUPPORT Human Clinical

"The clinical features of the 42 patients included developmental delay or regression (95%), epilepsy (73%), anaemia (71%), extrapyramidal symptoms (33%), dysphagia (23%), hypotonia (14%), and strabismus (7%)"

Supplies the 73% figure and the 42-patient denominator behind the FREQUENT band.

PMID:38454370 SUPPORT Human Clinical

"The mean number of ASMs used was 3.72 ± 1.36. Twenty cases had drug-refractory epilepsy"

Quantifies the refractoriness recorded as its own phenotype below.

Drug-Resistant Epilepsy Refractory drug response HP:0020174

Show evidence (1 reference)

PMID:38454370 SUPPORT Human Clinical

"The mean number of ASMs used was 3.72 ± 1.36. Twenty cases had drug-refractory epilepsy"

States both the medication burden and the refractory count, in the pooled 42-patient review.

Status epilepticus HP:0002133

Temporal: RECURRENT

Show evidence (2 references)

PMID:38454370 SUPPORT Human Clinical

"Twenty cases had drug-refractory epilepsy, fourteen had SE"

Gives the count of patients with status epilepticus in the pooled review.

PMID:32820246 SUPPORT Human Clinical

"CAD deficiency as a progressive EIEE with recurrent status epilepticus"

Confirms recurrence, which the temporality qualifier records.

Anisopoikilocytosis HP:0004823

Show evidence (2 references)

PMID:28007989 SUPPORT Human Clinical

"four children with global developmental delay, epileptic encephalopathy, and anaemia with anisopoikilocytosis"

The founding description pairing the film abnormality with the neurological syndrome.

PMID:32117025 SUPPORT Human Clinical

"all presented with DD, drug-resistant epilepsy, and anemia with anisopoikilocytosis"

Confirms the finding across every patient in an independent review of the early literature.

Increased HbA2 hemoglobin HP:0045048

Show evidence (1 reference)

PMID:37984840 SUPPORT Human Clinical

"We present a patient with macrocytic anaemia, elevated haemoglobin-A2 levels, anisocytosis, poikilocytosis and target cells in the blood smear, and mild developmental delay."

Direct observation of the raised HbA2 in an affected individual.

Delayed CNS myelination HP:0002188

Show evidence (1 reference)

PMID:38454370 SUPPORT Human Clinical

"Our study demonstrated that one-third of the reviewed cases had MRI abnormalities, with delayed myelination and brain atrophy being the main manifestations in infants and older children, respectively. The cerebral and/or cerebellar atrophy gradually progressed after 3.5 years of age."

Identifies delayed myelination as the main imaging manifestation in infants, which is the age-dependence this phenotype records.

🧬

Genetic Associations

1

CAD (Pathogenic Variants)

Gene: CAD hgnc:1424 relationship_type: CAUSATIVE

Show evidence (6 references)

PMID:28007989 SUPPORT Human Clinical

"We establish CAD as a gene confidently implicated in this neurometabolic disorder, characterized by co-occurrence of global developmental delay, dyserythropoietic anaemia and seizures."

The gene-disease association statement from the founding study.

PMID:32461667 SUPPORT In Vitro

"This condition is difficult to diagnose given the large size of CAD with over 1000 missense variants and the nonspecific clinical presentation."

Establishes the interpretive difficulty that makes functional validation necessary.

PMID:32461667 SUPPORT In Vitro

"We used the CAD-knockout complementation assay to test a total of 34 variants, identifying 16 as deleterious for CAD activity. Combination of these pathogenic variants confirmed 11 subjects with a CAD deficit"

Quantifies how many suspected variants were actually deleterious — 16 of 34 — and how many of 25 suspected individuals were confirmed.

+ 3 more references

💊

Medical Actions

1

Oral uridine supplementation

Action: Pharmacotherapy NCIT:C15986

Agent: uridine CHEBI:16704 uridine triacetate CHEBI:90914

Uridine bypasses the enzymatic block by entering the pyrimidine pool through the salvage route, which does not require CAD. It is given as uridine, uridine monophosphate or uridine triacetate. In treated patients seizures can stop immediately, development resumes, cerebellar atrophy can arrest and the blood film normalizes; supplementation was safe in the largest treated series. The disorder's authors recommend a trial in any patient with developmental delay, epilepsy and anaemia, in any patient with status epilepticus, and in any patient with neonatal seizures, until the diagnosis is excluded or six months have passed without benefit — an unusually permissive threshold that follows from the treatment's safety and the untreated mortality.

Mechanism Target:

ACTIVATES Intact Uridine Salvage Pathway — Supplying exogenous uridine drives the CAD-independent salvage route, which is the node this treatment acts through.

BYPASSES Pyrimidine Nucleotide and UDP-Sugar Pool Depletion — The depleted nucleotide and UDP-sugar pools are refilled without restoring CAD activity, which is why a complete enzymatic loss is still treatable.

Target Phenotypes: Epileptic encephalopathy HP:0200134 Anemia HP:0001903

Show evidence (4 references)

PMID:28007989 SUPPORT Human Clinical

"Supplementation of the two surviving children with oral uridine led to immediate cessation of seizures in both."

The founding demonstration of efficacy on the seizure endpoint.

PMID:25678555 SUPPORT In Vitro

"Uridine supplementation rescued these abnormalities, suggesting a potential therapy for this new glycosylation disorder."

The biochemical basis of the treatment — correction of the depleted pools in patient cells — which is the mechanism the target_mechanisms links record.

PMID:32820246 SUPPORT Human Clinical

"Supplementation with uridine, uridine monophosphate, or uridine triacetate in ten patients was safe and led to significant clinical improvement in most patients."

The largest treated series, establishing safety and the three acceptable preparations, with the qualifier that improvement was in most rather than all.

+ 1 more reference

🔬

Diagnosis

2

Exome sequencing with functional validation

Diagnosis rests on sequencing, but sequencing alone is not sufficient. Because CAD is large and prediction tools perform poorly on it, candidate variants are commonly returned as variants of unknown significance; functional validation in patient-derived fibroblasts, or in the CAD-knockout complementation assay, is what establishes the diagnosis. The assay is a CRISPR-generated human CAD-knockout line that cannot grow without uridine and is rescued by transfection with functional recombinant CAD.

whole exome sequencing NCIT:C101295

Show evidence (2 references)

PMID:32820246 SUPPORT Human Clinical

"With no biomarker available, the diagnosis relies on genetic testing and functional validation in patient-derived fibroblasts."

States the diagnostic pathway and, critically, the absence of a metabolic biomarker.

PMID:32461667 SUPPORT In Vitro

"Using CRISPR/Cas9, we generated a human CAD-knockout cell line that requires uridine supplements for survival. Transient transfection of the knockout cells with recombinant CAD restores growth in absence of uridine."

Describes the complementation assay that resolves variants of unknown significance.

Peripheral blood film

A blood film showing anisopoikilocytosis alongside anaemia, in a child with developmental delay and seizures, is the routine finding most likely to raise the diagnosis. It is not specific and is not a biomarker in the metabolic sense, but it is available everywhere and normalizes on treatment, so it doubles as a response measure.

Show evidence (2 references)

PMID:32117025 SUPPORT Human Clinical

"all presented with DD, drug-resistant epilepsy, and anemia with anisopoikilocytosis"

Establishes the triad in which the film finding is diagnostically useful.

PMID:28007989 SUPPORT Human Clinical

"Blood smears normalized and anaemia resolved."

Supports the use of the film as a treatment-response readout.

📈

Progression

4

Onset

Onset is early. Ninety per cent of reported patients presented before three years of age, at a mean of about 1.6 years, and of those with seizures 76% began before age two. Neonatal-onset presentations occur.

Show evidence (2 references)

PMID:38454370 SUPPORT Human Clinical

"Among them, 90% had onset before 3 years of age, with average of 1.6±1.8 years old."

The onset distribution from the pooled review.

PMID:32820246 SUPPORT Human Clinical

"add that milder courses with isolated developmental delay/intellectual disability can occur as well as onset with neonatal seizures"

Extends the onset range at both ends — neonatal seizures, and milder later-recognized courses.

Diagnostic delay

There is a large gap between onset and diagnosis: a mean age at diagnosis of 7.7 years against a mean onset of 1.6 years, with a range extending to 43 years. Because the disorder is treatable and untreated patients deteriorate, this delay is itself a determinant of outcome.

Show evidence (1 reference)

PMID:38454370 SUPPORT Human Clinical

"The age at diagnosis was 7.7 ± 10 years on average (school age) and ranged from 9 months to 43 years with a median of 5.5 years, only two cases were diagnosed in adult."

Quantifies the diagnostic delay against the onset figures above.

Untreated course and mortality

Untreated, the disease is progressive and can be lethal in early childhood. The pooled mortality was about 9.5%, and every reported death was in a patient who had not received uridine — the single most consequential observation in the literature on this disorder.

Show evidence (2 references)

PMID:38454370 SUPPORT Human Clinical

"The mortality rate was approximately 9.5%, with all reported deaths occurring in patients without uridine treatment."

The mortality figure together with its association with untreated status.

PMID:28007989 SUPPORT Human Clinical

"Two died aged 4 and 5 years after a neurodegenerative disease course."

The founding cohort's two deaths, both untreated, establishing the lethal natural history.

Treated course

Response to uridine can be rapid and substantial. In the founding cohort seizures ceased immediately in both treated children, and a four-year-old previously in a minimally conscious state began to communicate and walk with assistance within nine weeks. Response is not uniform: a sibling started at 14 years had only a modest response where his sister started at 5 had a dramatic one, which is the clearest available signal that timing matters.

Show evidence (2 references)

PMID:28007989 SUPPORT Human Clinical

"Supplementation of the two surviving children with oral uridine led to immediate cessation of seizures in both. A 4-year-old female, previously in a minimally conscious state, began to communicate and walk with assistance after 9 weeks of treatment."

The founding treatment observation, with its timescale.

PMID:33497533 SUPPORT Human Clinical

"Her older brother had a more severe course and only modest response to uridine started at 14 years old."

The within-family contrast that supports treatment timing as a determinant of response.

📊

Prevalence

1

Worldwide

Cases In Literature Ultra Rare

Forty-two patients had been reported in the literature as of the 2024 review, which is that publication's own pooled count. Cases have appeared since, so 42 is a dated lower bound rather than a current total. No population prevalence has been estimated, and the authors' own point is that the true figure is likely higher because pathogenic variants are commonly misfiled as variants of unknown significance.

Show evidence (1 reference)

PMID:38454370 SUPPORT Human Clinical

"To date, 42 cases of CAD variants have been reported"

The explicit literature count, kept as a count rather than converted into a population rate.

🔀

Differential Diagnoses

1

Conditions with similar clinical presentations that must be differentiated from Developmental and Epileptic Encephalopathy 50:

🧫

Experimental Models

2

CRISPR CAD-knockout human cell line CELL_LINE

A CRISPR/Cas9-generated human CAD-knockout line that cannot grow without uridine and is rescued by transfection with functional recombinant CAD. It is simultaneously the disease model and the diagnostic assay: growth rescue is the readout that classifies a patient variant as tolerated or deleterious, and therefore predicts who will benefit from uridine.

Organism

human NCBITaxon:9606

Publication

PMID:32461667

Pathograph links

Biallelic CAD Loss of Function recapitulates fidelity: high A complete CAD knockout reproduces the defining cellular consequence of the human lesion: uridine dependence for survival.

Limitations: A proliferating immortalized line is the compartment in which de novo synthesis matters most, so it models the metabolic lesion well and the neuronal consequence not at all. It also reports total loss rather than the graded residual activity of hypomorphic alleles.

Readouts

Growth without uridine supplementation

Direction: ABOLISHED

Interpretation: Loss of CAD makes the cell line dependent on exogenous uridine, which is the cellular phenotype the disease and its treatment both turn on.

Show evidence (1 reference)

PMID:32461667 SUPPORT In Vitro

"we generated a human CAD-knockout cell line that requires uridine supplements for survival"

The measurement and its direction.

Show evidence (1 reference)

PMID:32461667 SUPPORT In Vitro

"Transient transfection of the knockout cells with recombinant CAD restores growth in absence of uridine. This system determines missense variants that inactivate CAD and do not rescue the growth phenotype."

Establishes the rescue logic that makes the line informative for the trigger node.

Show evidence (1 reference)

PMID:32461667 SUPPORT In Vitro

"We designed a cell-based assay to test the pathogenicity of CAD variants, identifying 11 CAD-deficient individuals who could benefit from uridine therapy."

Establishes the system as informative for the disease and its direct clinical use.

Patient-derived dermal fibroblasts PRIMARY_CELL_CULTURE

Fibroblasts from affected individuals carry the biochemical lesion and are the system in which it was first characterized: impaired aspartate incorporation into RNA and DNA by the de novo route, depleted CTP, UTP and UDP-sugars, and correction of all of it by uridine.

Organism

human NCBITaxon:9606

Publication

PMID:25678555

Pathograph links

Pyrimidine Nucleotide and UDP-Sugar Pool Depletion measures fidelity: high Direct quantification of the depleted nucleotide and UDP-sugar pools in human patient cells, with uridine rescue.

Limitations: Fibroblasts are not an affected tissue; they report the cell-autonomous metabolic lesion but say nothing about why neurons and erythroid precursors specifically are damaged.

Readouts

CTP, UTP and UDP-activated sugar levels

Direction: DECREASED

Interpretation: Confirms in human cells that the block depletes both the nucleotide pool and the glycosylation donor pool.

Show evidence (1 reference)

PMID:25678555 SUPPORT In Vitro

"CTP, UTP and nearly all UDP-activated sugars that serve as donors for glycosylation were decreased."

The measurement and its direction.

Show evidence (1 reference)

PMID:25678555 SUPPORT In Vitro

"Metabolic flux studies showed impaired aspartate incorporation into RNA and DNA through the de novo synthesis pathway."

Establishes the system as carrying the disease biochemistry.

Show evidence (1 reference)

PMID:32820246 SUPPORT Human Clinical

"the diagnosis relies on genetic testing and functional validation in patient-derived fibroblasts"

Establishes that this system is not merely a research model but part of the diagnostic pathway.

🐁

Animal Models

1

CAD-deficient Bengal cat Genetic

A naturally occurring feline model. A four-month-old Bengal kitten with intractable seizures and abnormal behaviour carried a homozygous CAD variant predicted to disrupt oligomerization of the C-terminal ATCase domain, and the variant failed to rescue growth in the human CAD-knockout complementation assay. Four further carriers were found among 110 unaffected Bengals, so the allele segregates in the breed. This is a spontaneous large-animal model of a disorder whose human cohort is only a few dozen people.

Species

Cat

Genotype

CAD p.Ser2015Asn homozygous

Genes

CAD hgnc:1424

Publication

PMID:40251393

Pathograph links

Biallelic CAD Loss of Function recapitulates fidelity: moderate The feline variant abolishes CAD function in the same complementation assay used to classify human variants, and the affected kitten had intractable seizures.

Limitations: A single affected animal, characterized clinically rather than neuropathologically; the haematological arm of the human phenotype was not reported, and no uridine trial was performed, so the model's treatment responsiveness is inferred rather than demonstrated.

Readouts

Growth rescue of CAD-knockout cells by the feline variant

Direction: ABOLISHED

Interpretation: The mutant protein cannot support growth without uridine, establishing loss of function rather than a benign substitution.

Show evidence (1 reference)

PMID:40251393 SUPPORT Model Organism

"In a CAD-knockout human cell line dependent on uridine, the recombinant expression of human wildtype CAD, but not of the Asn2015 mutant, restored cell growth without uridine, demonstrating that the p.Ser2015Asn variant disrupts CAD function and is pathogenic."

The functional measurement and its direction.

Show evidence (1 reference)

PMID:40251393 SUPPORT Model Organism

"Here, we report a novel variant in the feline CAD gene in a 4-month-old Bengal kitten with intractable seizures and abnormal behavior."

Establishes the model as an informative naturally occurring counterpart of the human trigger lesion.

Show evidence (1 reference)

PMID:40251393 SUPPORT Model Organism

"CAD-deficient Bengal cats might serve as a valuable spontaneous large animal model to further investigate the pathogenic mechanisms of this rare epileptic encephalopathy in humans."

The authors' own framing of the animal as a model for the human disease, quoted with the hedge they used.

{ }

Source YAML

click to show

name: Developmental and Epileptic Encephalopathy 50
creation_date: "2026-08-24T00:00:00Z"
description: >-
  DEE50, or CAD deficiency, is an autosomal recessive neurometabolic disorder
  caused by biallelic variants in CAD, the single 1.5 MDa multienzyme particle
  that carries the first three committed reactions of de novo pyrimidine
  biosynthesis. Loss of activity depletes the UTP, CTP and UDP-sugar pools of
  cells that depend on de novo synthesis, producing a triad of global
  developmental delay or regression, drug-refractory epilepsy with recurrent
  status epilepticus, and a dyserythropoietic anaemia with anisopoikilocytosis.
  Untreated, the course is progressive and can be lethal in early childhood.
  What makes the entry unusual is that the block sits at the entry to the
  pathway, upstream of where de novo and salvage converge, so oral uridine
  bypasses it entirely: seizures can stop within days and the haematological
  abnormalities resolve. There is no metabolic biomarker, diagnosis rests on
  sequencing plus functional validation, and most reported deaths were in
  patients who never received uridine.
category: Mendelian
parents:
- autosomal recessive disease
- inborn error of metabolism
synonyms:
- DEE50
- CAD deficiency
- early infantile epileptic encephalopathy 50
- EIEE50
disease_term:
  preferred_term: developmental and epileptic encephalopathy, 50
  term:
    id: MONDO:0014647
    label: developmental and epileptic encephalopathy, 50
classifications:
  harrisons_chapter:
  - classification_value: ENDOCRINOLOGY_METABOLISM
    notes: >-
      Placed as an inborn error of metabolism (de novo pyrimidine biosynthesis)
      rather than under a neurology chapter, because the treatable metabolic
      lesion is what defines the entity. Harrison's does not list DEE50 by name;
      this is a mechanism-based placement, not a textbook citation.
inheritance:
- name: Autosomal recessive inheritance
  description: >-
    DEE50 is autosomal recessive, caused by biallelic CAD variants in the
    homozygous or compound heterozygous state. Reported families include both
    consanguineous unions and unrelated compound heterozygotes.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  expressivity: VARIABLE
  evidence:
  - reference: PMID:32820246
    reference_title: "Expanding the clinical and genetic spectrum of CAD deficiency: an epileptic encephalopathy treatable with uridine supplementation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Biallelic CAD variants underlie CAD deficiency"
    explanation: >-
      Establishes biallelic causation and names the salvage route that the
      treatment exploits.
  - reference: PMID:38454370
    reference_title: "Novel CAD gene mutations in a boy with developmental and epileptic encephalopathy 50 with dramatic response to uridine therapy: a case report and a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Five patients had consanguineous parents, and 12 had a reported family history."
    explanation: >-
      Documents both consanguineous and familial occurrence across the
      42-patient literature review, consistent with recessive inheritance.
pathophysiology:
- name: Biallelic CAD Loss of Function
  biological_scale: MOLECULAR
  role: trigger
  description: >-
    CAD is a single 2,225-residue polypeptide that assembles into a roughly
    1.5 MDa hexameric particle carrying four catalytic domains in one chain:
    glutamine amidotransferase, carbamoyl phosphate synthetase II, aspartate
    transcarbamoylase and dihydroorotase. The covalent fusion of these
    activities into one particle is unique to animals. Biallelic variants
    reduce or abolish activity; missense alleles predominate and can act by
    disrupting oligomerization of a domain rather than by destroying a catalytic
    site — the feline variant below is a worked example of that route. A
    hypomorphic allelic class retaining partial activity produces a milder,
    primarily haematological phenotype.
  genes:
  - preferred_term: CAD
    term:
      id: hgnc:1424
      label: CAD
  molecular_functions:
  - preferred_term: carbamoyl-phosphate synthase (glutamine-hydrolyzing) activity
    term:
      id: GO:0004088
      label: carbamoyl-phosphate synthase (glutamine-hydrolyzing) activity
    modifier: DECREASED
  - preferred_term: aspartate carbamoyltransferase activity
    term:
      id: GO:0004070
      label: aspartate carbamoyltransferase activity
    modifier: DECREASED
  - preferred_term: dihydroorotase activity
    term:
      id: GO:0004151
      label: dihydroorotase activity
    modifier: DECREASED
  evidence:
  - reference: PMID:40251393
    reference_title: "Epileptic encephalopathy in a young Bengal cat caused by CAD deficiency."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The variant, XP_011279586.1:p.(Ser2015Asn), was predicted to affect the oligomerization of the C-terminal aspartate transcarbamylase (ATCase) domain of CAD."
    explanation: >-
      A worked example of the oligomerization route to loss of function, in
      which the substitution disrupts domain assembly rather than a catalytic
      site. Evidence source is MODEL_ORGANISM because the variant is feline.
  - reference: PMID:34288185
    reference_title: "Deciphering CAD: Structure and function of a mega-enzymatic pyrimidine factory in health and disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "CAD is a 1.5 MDa particle formed by hexameric association of a 250 kDa protein divided into different enzymatic domains, each catalyzing one of the initial reactions for de novo biosynthesis of pyrimidine nucleotides: glutaminase-dependent Carbamoyl phosphate synthetase, Aspartate transcarbamoylase, and Dihydroorotase."
    explanation: >-
      Establishes the architecture and the catalytic domains whose loss defines
      the trigger, and is the source for the glutamine-hydrolyzing (not
      ammonia-dependent) carbamoyl phosphate synthetase activity bound above.
  - reference: PMID:34288185
    reference_title: "Deciphering CAD: Structure and function of a mega-enzymatic pyrimidine factory in health and disease."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "the covalent linkage of the first enzymatic activities into a multienzymatic CAD particle is unique to animals"
    explanation: >-
      Supports the statement that the multienzyme fusion is animal-specific,
      which is why a single gene defect removes three sequential activities.
  downstream:
  - target: Impaired De Novo Pyrimidine Biosynthesis
    causal_link_type: DIRECT
    description: >-
      Loss of the CAD activities blocks the first three of the six reactions
      that make UMP.
    evidence:
    - reference: PMID:25678555
      reference_title: "Biallelic mutations in CAD, impair de novo pyrimidine biosynthesis and decrease glycosylation precursors."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The tri-functional enzyme contains carbamoyl-phosphate synthetase 2 (CPS2), aspartate transcarbamylase (ATCase) and dihydroorotase (DHOase) activities, which comprise the first three of six reactions required for de novo pyrimidine biosynthesis."
      explanation: >-
        States precisely which steps of the pathway the enzyme carries, and so
        which are lost.
- name: Impaired De Novo Pyrimidine Biosynthesis
  biological_scale: MOLECULAR
  role: central_effector
  description: >-
    With CAD inactive, flux through de novo pyrimidine synthesis fails. Metabolic
    flux studies in patient fibroblasts show impaired incorporation of aspartate
    into RNA and DNA by this route. This is the rate-limiting lesion of the
    disease, and its position matters therapeutically: it lies upstream of the
    point at which the de novo and salvage routes converge, which is what leaves
    the disease bypassable.
  biological_processes:
  - preferred_term: "'de novo' UMP biosynthetic process"
    term:
      id: GO:0044205
      label: "'de novo' UMP biosynthetic process"
    modifier: DECREASED
  - preferred_term: "'de novo' pyrimidine nucleobase biosynthetic process"
    term:
      id: GO:0006207
      label: "'de novo' pyrimidine nucleobase biosynthetic process"
    modifier: DECREASED
  cell_types:
  - preferred_term: Dermal fibroblast
    term:
      id: CL:0002620
      label: skin fibroblast
  evidence:
  - reference: PMID:25678555
    reference_title: "Biallelic mutations in CAD, impair de novo pyrimidine biosynthesis and decrease glycosylation precursors."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Metabolic flux studies showed impaired aspartate incorporation into RNA and DNA through the de novo synthesis pathway."
    explanation: >-
      Direct measurement of the blocked flux in cells from an affected
      individual.
  downstream:
  - target: Pyrimidine Nucleotide and UDP-Sugar Pool Depletion
    causal_link_type: DIRECT
    description: >-
      The blocked pathway fails to supply its downstream products.
    evidence:
    - reference: PMID:25678555
      reference_title: "Biallelic mutations in CAD, impair de novo pyrimidine biosynthesis and decrease glycosylation precursors."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "In addition, CTP, UTP and nearly all UDP-activated sugars that serve as donors for glycosylation were decreased."
      explanation: >-
        Measures the depleted pools directly downstream of the blocked flux, in
        the same patient cells.
- name: Pyrimidine Nucleotide and UDP-Sugar Pool Depletion
  biological_scale: CELLULAR
  description: >-
    The consequence is not only a nucleic-acid precursor shortage. CTP and UTP
    fall, and so do nearly all UDP-activated sugars, which are the donor
    substrates for glycosylation. The original report of the disease framed it
    as a glycosylation disorder for exactly this reason. Cells that rely on de
    novo synthesis rather than salvage — proliferating cells such as erythroid
    precursors, and neurons during development — are the ones that feel it.
  biological_processes:
  - preferred_term: "'de novo' UMP biosynthetic process"
    term:
      id: GO:0044205
      label: "'de novo' UMP biosynthetic process"
    modifier: DECREASED
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  - preferred_term: Erythroid lineage cell
    term:
      id: CL:0000764
      label: erythroid lineage cell
  evidence:
  - reference: PMID:25678555
    reference_title: "Biallelic mutations in CAD, impair de novo pyrimidine biosynthesis and decrease glycosylation precursors."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "CTP, UTP and nearly all UDP-activated sugars that serve as donors for glycosylation were decreased. Uridine supplementation rescued these abnormalities, suggesting a potential therapy for this new glycosylation disorder."
    explanation: >-
      Establishes both arms of the depletion — nucleotide and glycosylation
      donor — and that uridine corrects them, which is the mechanistic basis of
      the treatment node below.
  downstream:
  - target: Dyserythropoiesis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Erythroid precursors are proliferative and depend on de novo supply.
    evidence:
    - reference: PMID:32820246
      reference_title: "Expanding the clinical and genetic spectrum of CAD deficiency: an epileptic encephalopathy treatable with uridine supplementation."
      supports: SUPPORT
      directness: INDIRECT
      evidence_source: HUMAN_CLINICAL
      snippet: "Our study confirms CAD deficiency as a progressive EIEE with recurrent status epilepticus, loss of skills, and dyserythropoietic anemia."
      explanation: >-
        Classified INDIRECT: the source establishes that dyserythropoietic
        anaemia is part of the disease, but does not demonstrate the
        intervening steps from nucleotide depletion to defective erythropoiesis.
  - target: Progressive Neuronal Injury and Brain Atrophy
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The developing and mature brain is the other affected compartment. How
      pool depletion produces neuronal injury specifically is not established —
      see the gap_pyrimidine_depletion_to_neuronal_injury discussion.
    evidence:
    - reference: PMID:32820246
      reference_title: "Expanding the clinical and genetic spectrum of CAD deficiency: an epileptic encephalopathy treatable with uridine supplementation."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Our study confirms CAD deficiency as a progressive EIEE with recurrent status epilepticus, loss of skills, and dyserythropoietic anemia."
      explanation: >-
        Classified PARTIAL: establishes the progressive neurological course
        that this node represents, without evidencing the mechanism connecting
        it to the metabolic lesion.
- name: Dyserythropoiesis
  biological_scale: TISSUE
  description: >-
    The haematological arm is a dyserythropoietic anaemia with a strikingly
    abnormal blood film — anisopoikilocytosis, with target cells and
    poikilocytes described. It is one of the few features that can point at the
    diagnosis before sequencing, and it resolves on uridine. In the hypomorphic
    allelic class it can be the presenting and near-only feature.
  cell_types:
  - preferred_term: Erythroid lineage cell
    term:
      id: CL:0000764
      label: erythroid lineage cell
  evidence:
  - reference: PMID:28007989
    reference_title: "CAD mutations and uridine-responsive epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Exome sequencing in three families identified biallelic CAD mutations in four children with global developmental delay, epileptic encephalopathy, and anaemia with anisopoikilocytosis."
    explanation: >-
      The founding description of the haematological phenotype alongside the
      neurological one.
  - reference: PMID:28007989
    reference_title: "CAD mutations and uridine-responsive epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Blood smears normalized and anaemia resolved."
    explanation: >-
      Establishes that this node is reversible on uridine, which is what makes
      it usable as a treatment-response readout.
- name: Progressive Neuronal Injury and Brain Atrophy
  biological_scale: TISSUE
  description: >-
    Neuroimaging shows brain atrophy in most of the patients who have an
    abnormal MRI, involving the whole brain or the cerebellum, with delayed
    myelination and hydrocephalus reported less often. The atrophy is
    progressive if untreated, and at least one sibling pair showed that uridine
    can arrest it. This entry does not declare conformance to
    cerebellar_purkinje_degeneration: cerebellar atrophy is an imaging finding
    here, and no Purkinje-cell-specific lesion has been demonstrated in CAD
    deficiency.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:38454370
    reference_title: "Novel CAD gene mutations in a boy with developmental and epileptic encephalopathy 50 with dramatic response to uridine therapy: a case report and a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our study demonstrated that one-third of the reviewed cases had MRI abnormalities, with delayed myelination and brain atrophy being the main manifestations in infants and older children, respectively. The cerebral and/or cerebellar atrophy gradually progressed after 3.5 years of age."
    explanation: >-
      Gives the imaging picture and its age dependence, and states that the
      atrophy is progressive rather than static.
  - reference: PMID:33497533
    reference_title: "Uridine-responsive epileptic encephalopathy due to inherited variants in CAD: A Tale of Two Siblings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "uridine started at age 5 resulted in dramatic improvements in seizure control and development, cessation of cerebellar atrophy, and resolution of hematological abnormalities"
    explanation: >-
      Shows the atrophy is an active, arrestable process rather than a fixed
      developmental malformation.
  downstream:
  - target: Epileptic Encephalopathy
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Ongoing neuronal injury accompanies the seizure disorder and the loss of
      developmental skills.
    evidence:
    - reference: PMID:38454370
      reference_title: "Novel CAD gene mutations in a boy with developmental and epileptic encephalopathy 50 with dramatic response to uridine therapy: a case report and a review of the literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "DEE 50 has early onset, refractory seizures, even status epilepticus leading to death, with favorable response to treatment with oral uridine."
      explanation: >-
        Classified PARTIAL: the source establishes that the epilepsy and the
        progressive course co-occur, not that the atrophy causes the seizures.
- name: Epileptic Encephalopathy
  biological_scale: ORGANISM
  role: consequence
  description: >-
    The clinical endpoint is an early-onset, drug-refractory epileptic
    encephalopathy with recurrent status epilepticus and loss of acquired
    skills, on a background of developmental delay. Most patients need multiple
    antiseizure medicines and remain refractory on them. This entry does not
    declare conformance to epilepsy_excitation_inhibition_imbalance: no
    excitation-inhibition measurement exists in CAD deficiency, and asserting
    that module's mechanism would substitute a plausible route for an
    evidenced one.
  evidence:
  - reference: PMID:32820246
    reference_title: "Expanding the clinical and genetic spectrum of CAD deficiency: an epileptic encephalopathy treatable with uridine supplementation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our study confirms CAD deficiency as a progressive EIEE with recurrent status epilepticus, loss of skills, and dyserythropoietic anemia."
    explanation: >-
      Characterizes the endpoint syndrome in a 20-patient series.
  - reference: PMID:38454370
    reference_title: "Novel CAD gene mutations in a boy with developmental and epileptic encephalopathy 50 with dramatic response to uridine therapy: a case report and a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Twenty cases had drug-refractory epilepsy, fourteen had SE, and one had a history of temporal lobectomy and ventriculoperitoneal shunt surgery."
    explanation: >-
      Quantifies refractoriness and status epilepticus in the pooled cohort.
- name: Intact Uridine Salvage Pathway
  biological_scale: MOLECULAR
  role: modifier
  description: >-
    This node is what the disease is bypassable through, not a lesion. Pyrimidines
    can be recycled from uridine by a route that does not use CAD and enters the
    pathway downstream of the block, so supplying uridine restores the depleted
    pools without repairing the enzyme. It is curated as a node so the treatment
    below can point at it. The contrast with DTYMK deficiency is instructive and
    is drawn out in that entry: DTYMK sits downstream of where de novo and
    salvage converge, so the same trick does not work there.
  biological_processes:
  - preferred_term: pyrimidine nucleoside salvage
    term:
      id: GO:0043097
      label: pyrimidine nucleoside salvage
  evidence:
  - reference: PMID:28007989
    reference_title: "CAD mutations and uridine-responsive epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CAD encodes a multifunctional enzyme involved in de novo pyrimidine biosynthesis. Alternatively, pyrimidines can be recycled from uridine."
    explanation: >-
      States the existence of the CAD-independent route that the therapy uses.
  - reference: PMID:32820246
    reference_title: "Expanding the clinical and genetic spectrum of CAD deficiency: an epileptic encephalopathy treatable with uridine supplementation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "an error of pyrimidine de novo biosynthesis amenable to treatment via the uridine salvage pathway"
    explanation: >-
      Names the salvage pathway as the treatment route, which is the role this
      node plays in the pathograph.
phenotypes:
- name: Global developmental delay
  category: Neurologic
  description: >-
    Developmental delay, often with frank regression of acquired skills, is the
    most frequent feature of the disorder, present in 95% of the 42 patients in
    the pooled literature review. Regression rather than static delay is what
    distinguishes the untreated course.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:38454370
    reference_title: "Novel CAD gene mutations in a boy with developmental and epileptic encephalopathy 50 with dramatic response to uridine therapy: a case report and a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The clinical features of the 42 patients included developmental delay or regression (95%), epilepsy (73%), anaemia (71%), extrapyramidal symptoms (33%), dysphagia (23%), hypotonia (14%), and strabismus (7%)"
    explanation: >-
      Gives the 95% figure with an explicit 42-patient denominator, which is
      what the VERY_FREQUENT band rests on.
- name: Developmental regression
  category: Neurologic
  description: >-
    Loss of previously acquired skills is a defining feature of the untreated
    course and is the endpoint that uridine most visibly reverses. It is pooled
    with delay in the 95% figure, so no separate band is assigned.
  phenotype_term:
    preferred_term: Developmental regression
    term:
      id: HP:0002376
      label: Developmental regression
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:32820246
    reference_title: "Expanding the clinical and genetic spectrum of CAD deficiency: an epileptic encephalopathy treatable with uridine supplementation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our study confirms CAD deficiency as a progressive EIEE with recurrent status epilepticus, loss of skills, and dyserythropoietic anemia."
    explanation: >-
      Names loss of skills as a confirmed feature of the disorder.
- name: Epileptic encephalopathy
  category: Neurologic
  description: >-
    Epilepsy is present in 73% of reported patients and is characteristically
    drug-refractory: the mean number of antiseizure medicines used was almost
    four, and twenty of the reviewed cases were refractory on them. Onset is
    early, with 76% of those with seizures starting before age two.
    Refractoriness is curated separately, as its own phenotype below.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Epileptic encephalopathy
    term:
      id: HP:0200134
      label: Epileptic encephalopathy
  evidence:
  - reference: PMID:38454370
    reference_title: "Novel CAD gene mutations in a boy with developmental and epileptic encephalopathy 50 with dramatic response to uridine therapy: a case report and a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The clinical features of the 42 patients included developmental delay or regression (95%), epilepsy (73%), anaemia (71%), extrapyramidal symptoms (33%), dysphagia (23%), hypotonia (14%), and strabismus (7%)"
    explanation: >-
      Supplies the 73% figure and the 42-patient denominator behind the
      FREQUENT band.
  - reference: PMID:38454370
    reference_title: "Novel CAD gene mutations in a boy with developmental and epileptic encephalopathy 50 with dramatic response to uridine therapy: a case report and a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The mean number of ASMs used was 3.72 ± 1.36. Twenty cases had drug-refractory epilepsy"
    explanation: >-
      Quantifies the refractoriness recorded as its own phenotype below.
- name: Drug-Resistant Epilepsy
  category: Neurologic
  description: >-
    The epilepsy characteristically resists antiseizure medication: patients in
    the pooled review were on a mean of 3.72 medicines, and twenty of the
    forty-two were refractory on them. No band is assigned. Twenty of 42 is 48%,
    which would fall in FREQUENT, but the denominator for refractoriness is
    properly the 73% who have epilepsy at all, not the whole cohort, and the
    source does not state it that way.
  phenotype_term:
    preferred_term: Refractory drug response
    term:
      id: HP:0020174
      label: Refractory drug response
  evidence:
  - reference: PMID:38454370
    reference_title: "Novel CAD gene mutations in a boy with developmental and epileptic encephalopathy 50 with dramatic response to uridine therapy: a case report and a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The mean number of ASMs used was 3.72 ± 1.36. Twenty cases had drug-refractory epilepsy"
    explanation: >-
      States both the medication burden and the refractory count, in the pooled
      42-patient review.
- name: Status epilepticus
  category: Neurologic
  description: >-
    Recurrent status epilepticus is a defining complication and, in the untreated
    course, a route to death. Fourteen of the reviewed patients had it.
  phenotype_term:
    preferred_term: Status epilepticus
    term:
      id: HP:0002133
      label: Status epilepticus
    temporality: RECURRENT
  evidence:
  - reference: PMID:38454370
    reference_title: "Novel CAD gene mutations in a boy with developmental and epileptic encephalopathy 50 with dramatic response to uridine therapy: a case report and a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Twenty cases had drug-refractory epilepsy, fourteen had SE"
    explanation: >-
      Gives the count of patients with status epilepticus in the pooled review.
  - reference: PMID:32820246
    reference_title: "Expanding the clinical and genetic spectrum of CAD deficiency: an epileptic encephalopathy treatable with uridine supplementation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "CAD deficiency as a progressive EIEE with recurrent status epilepticus"
    explanation: >-
      Confirms recurrence, which the temporality qualifier records.
- name: Anemia
  category: Hematologic
  description: >-
    Anaemia is present in 71% of reported patients. It is dyserythropoietic, and
    the reported red-cell size varies — normocytic most often, but macrocytic
    and microcytic cases are both described, so the entry binds the generic term
    rather than a size-specific one.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Anemia
    term:
      id: HP:0001903
      label: Anemia
  evidence:
  - reference: PMID:38454370
    reference_title: "Novel CAD gene mutations in a boy with developmental and epileptic encephalopathy 50 with dramatic response to uridine therapy: a case report and a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The clinical features of the 42 patients included developmental delay or regression (95%), epilepsy (73%), anaemia (71%), extrapyramidal symptoms (33%), dysphagia (23%), hypotonia (14%), and strabismus (7%)"
    explanation: >-
      Supplies the 71% figure and the denominator behind the FREQUENT band.
- name: Anisopoikilocytosis
  category: Hematologic
  description: >-
    The blood film shows red cells varying in both size and shape. It is the
    single most diagnostically suggestive routine finding in the disorder, and
    it normalizes on uridine. No frequency band is assigned: the pooled review
    reports morphology only for the subset in whom a film was described.
  phenotype_term:
    preferred_term: Anisopoikilocytosis
    term:
      id: HP:0004823
      label: Anisopoikilocytosis
  evidence:
  - reference: PMID:28007989
    reference_title: "CAD mutations and uridine-responsive epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "four children with global developmental delay, epileptic encephalopathy, and anaemia with anisopoikilocytosis"
    explanation: >-
      The founding description pairing the film abnormality with the
      neurological syndrome.
  - reference: PMID:32117025
    reference_title: "A Patient With CAD Deficiency Responsive to Uridine and Literature Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "all presented with DD, drug-resistant epilepsy, and anemia with anisopoikilocytosis"
    explanation: >-
      Confirms the finding across every patient in an independent review of the
      early literature.
- name: Macrocytic anemia
  category: Hematologic
  description: >-
    In the hypomorphic allelic class the haematological arm can dominate: a
    patient with biallelic hypomorphic CAD variants presented with macrocytic
    anaemia, elevated haemoglobin A2, anisocytosis, poikilocytosis and target
    cells on the film, with only mild developmental delay and no epileptic
    encephalopathy — and still responded to uridine.
  phenotype_term:
    preferred_term: Macrocytic anemia
    term:
      id: HP:0001972
      label: Macrocytic anemia
  evidence:
  - reference: PMID:37984840
    reference_title: "Biallelic hypomorphic variants in CAD cause uridine-responsive macrocytic anaemia with elevated haemoglobin-A2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We present a patient with macrocytic anaemia, elevated haemoglobin-A2 levels, anisocytosis, poikilocytosis and target cells in the blood smear, and mild developmental delay."
    explanation: >-
      Documents the milder, haematology-dominant end of the allelic spectrum.
- name: Increased HbA2 hemoglobin
  category: Hematologic
  description: >-
    Elevated haemoglobin A2 was reported in the hypomorphic case and is notable
    because it can misdirect towards a thalassaemia trait.
  phenotype_term:
    preferred_term: Increased HbA2 hemoglobin
    term:
      id: HP:0045048
      label: Increased HbA2 hemoglobin
  evidence:
  - reference: PMID:37984840
    reference_title: "Biallelic hypomorphic variants in CAD cause uridine-responsive macrocytic anaemia with elevated haemoglobin-A2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We present a patient with macrocytic anaemia, elevated haemoglobin-A2 levels, anisocytosis, poikilocytosis and target cells in the blood smear, and mild developmental delay."
    explanation: >-
      Direct observation of the raised HbA2 in an affected individual.
- name: Ataxia
  category: Neurologic
  description: >-
    A movement disorder is a frequent and, until recently, under-recognized
    feature, present in about a third of reported patients; ataxia is its
    commonest component. Per-symptom counts appear only in the review's summary
    table, which does not extract as quotable prose, so the band here rests on
    the category-level figure stated in the text.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:38454370
    reference_title: "Novel CAD gene mutations in a boy with developmental and epileptic encephalopathy 50 with dramatic response to uridine therapy: a case report and a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "highlights the high incidence of extrapyramidal symptoms in approximately one-third of the cases"
    explanation: >-
      Puts the extrapyramidal category, of which ataxia is the commonest
      component, at about one-third of patients — the basis for the FREQUENT
      band.
  - reference: PMID:32820246
    reference_title: "Expanding the clinical and genetic spectrum of CAD deficiency: an epileptic encephalopathy treatable with uridine supplementation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We further refine the phenotype by reporting a movement disorder as a frequent feature"
    explanation: >-
      Independent confirmation that the movement disorder is frequent rather
      than incidental.
- name: Tremor
  category: Neurologic
  description: >-
    Tremor accompanies the ataxia as part of the extrapyramidal picture the
    2024 review singles out as previously underappreciated. No frequency band is
    assigned, because the tremor-specific count is only in a table.
  phenotype_term:
    preferred_term: Tremor
    term:
      id: HP:0001337
      label: Tremor
  evidence:
  - reference: PMID:38454370
    reference_title: "Novel CAD gene mutations in a boy with developmental and epileptic encephalopathy 50 with dramatic response to uridine therapy: a case report and a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Some manifestations, such as extrapyramidal symptoms, dysphagia, and hypotonia, have been underappreciated in previous reports."
    explanation: >-
      Classified PARTIAL: tremor is one component of the extrapyramidal
      category this sentence covers. The per-symptom tremor count appears only
      in the review's summary table, which does not extract as quotable prose.
- name: Dysphagia
  category: Gastrointestinal
  description: >-
    Dysphagia was present in 23% of the pooled cohort and is listed among the
    phenotypes the earlier literature had overlooked.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:38454370
    reference_title: "Novel CAD gene mutations in a boy with developmental and epileptic encephalopathy 50 with dramatic response to uridine therapy: a case report and a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The clinical features of the 42 patients included developmental delay or regression (95%), epilepsy (73%), anaemia (71%), extrapyramidal symptoms (33%), dysphagia (23%), hypotonia (14%), and strabismus (7%)"
    explanation: >-
      Supplies the 23% figure and denominator behind the OCCASIONAL band.
- name: Hypotonia
  category: Neurologic
  description: >-
    Hypotonia was recorded in 14% of the pooled cohort.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:38454370
    reference_title: "Novel CAD gene mutations in a boy with developmental and epileptic encephalopathy 50 with dramatic response to uridine therapy: a case report and a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "dysphagia (23%), hypotonia (14%), and strabismus (7%)"
    explanation: >-
      Supplies the 14% figure behind the OCCASIONAL band.
- name: Strabismus
  category: Ophthalmologic
  description: >-
    Strabismus was recorded in 7% of the pooled cohort, the least frequent of
    the features the 2024 review tabulated with a denominator.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Strabismus
    term:
      id: HP:0000486
      label: Strabismus
  evidence:
  - reference: PMID:38454370
    reference_title: "Novel CAD gene mutations in a boy with developmental and epileptic encephalopathy 50 with dramatic response to uridine therapy: a case report and a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "dysphagia (23%), hypotonia (14%), and strabismus (7%)"
    explanation: >-
      Supplies the 7% figure against the 42-patient denominator behind the
      OCCASIONAL band.
- name: Cerebral atrophy
  category: Neurologic
  description: >-
    Brain atrophy is one of the two main imaging manifestations, dominating in
    older children where delayed myelination dominates in infants, and it
    progresses after about three and a half years of age.
  phenotype_term:
    preferred_term: Cerebral atrophy
    term:
      id: HP:0002059
      label: Cerebral atrophy
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:38454370
    reference_title: "Novel CAD gene mutations in a boy with developmental and epileptic encephalopathy 50 with dramatic response to uridine therapy: a case report and a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our study demonstrated that one-third of the reviewed cases had MRI abnormalities, with delayed myelination and brain atrophy being the main manifestations in infants and older children, respectively. The cerebral and/or cerebellar atrophy gradually progressed after 3.5 years of age."
    explanation: >-
      States brain atrophy as a main imaging manifestation in older children and
      records that it progresses, which the clinical_course qualifier captures.
- name: Cerebellar atrophy
  category: Neurologic
  description: >-
    Cerebellar atrophy occurs alongside cerebral atrophy and progresses after
    about three and a half years of age; in one sibling pair its progression
    stopped after uridine was started.
  phenotype_term:
    preferred_term: Cerebellar atrophy
    term:
      id: HP:0001272
      label: Cerebellar atrophy
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:38454370
    reference_title: "Novel CAD gene mutations in a boy with developmental and epileptic encephalopathy 50 with dramatic response to uridine therapy: a case report and a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our study demonstrated that one-third of the reviewed cases had MRI abnormalities, with delayed myelination and brain atrophy being the main manifestations in infants and older children, respectively. The cerebral and/or cerebellar atrophy gradually progressed after 3.5 years of age."
    explanation: >-
      Records cerebellar atrophy alongside cerebral atrophy and states that it
      progresses, which is what the clinical_course qualifier asserts.
  - reference: PMID:33497533
    reference_title: "Uridine-responsive epileptic encephalopathy due to inherited variants in CAD: A Tale of Two Siblings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We report two siblings with intractable epilepsy, developmental regression, and progressive cerebellar atrophy due to biallelic variants in the gene CAD."
    explanation: >-
      Documents the progressive character that the clinical_course qualifier
      records.
- name: Delayed CNS myelination
  category: Neurologic
  description: >-
    Delayed myelination is the imaging finding that dominates in infancy, before
    atrophy becomes the leading abnormality in older children.
  phenotype_term:
    preferred_term: Delayed CNS myelination
    term:
      id: HP:0002188
      label: Delayed CNS myelination
  evidence:
  - reference: PMID:38454370
    reference_title: "Novel CAD gene mutations in a boy with developmental and epileptic encephalopathy 50 with dramatic response to uridine therapy: a case report and a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our study demonstrated that one-third of the reviewed cases had MRI abnormalities, with delayed myelination and brain atrophy being the main manifestations in infants and older children, respectively. The cerebral and/or cerebellar atrophy gradually progressed after 3.5 years of age."
    explanation: >-
      Identifies delayed myelination as the main imaging manifestation in
      infants, which is the age-dependence this phenotype records.
genetic:
- name: CAD
  gene_term:
    preferred_term: CAD
    term:
      id: hgnc:1424
      label: CAD
  association: Pathogenic Variants
  relationship_type: CAUSATIVE
  notes: >-
    CAD is the only gene implicated. Missense variants dominate the reported
    spectrum, with nonsense and splice-site alleles making up the remainder.
    Two features complicate variant interpretation and are the practical reason
    the disorder is under-recognized: the gene is very large with over a
    thousand catalogued missense variants, and prediction tools perform poorly
    on it, so pathogenic alleles are frequently returned as variants of unknown
    significance. A cell-based complementation assay is what resolves them, and
    it reclassified more than half of a suspected cohort as not CAD-deficient.
    A hypomorphic allelic class retains partial activity and produces a
    primarily haematological phenotype.
  evidence:
  - reference: PMID:28007989
    reference_title: "CAD mutations and uridine-responsive epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We establish CAD as a gene confidently implicated in this neurometabolic disorder, characterized by co-occurrence of global developmental delay, dyserythropoietic anaemia and seizures."
    explanation: >-
      The gene-disease association statement from the founding study.
  - reference: PMID:32461667
    reference_title: "Cell-based analysis of CAD variants identifies individuals likely to benefit from uridine therapy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "This condition is difficult to diagnose given the large size of CAD with over 1000 missense variants and the nonspecific clinical presentation."
    explanation: >-
      Establishes the interpretive difficulty that makes functional validation
      necessary.
  - reference: PMID:32461667
    reference_title: "Cell-based analysis of CAD variants identifies individuals likely to benefit from uridine therapy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We used the CAD-knockout complementation assay to test a total of 34 variants, identifying 16 as deleterious for CAD activity. Combination of these pathogenic variants confirmed 11 subjects with a CAD deficit"
    explanation: >-
      Quantifies how many suspected variants were actually deleterious — 16 of
      34 — and how many of 25 suspected individuals were confirmed.
  - reference: PMID:32820246
    reference_title: "Expanding the clinical and genetic spectrum of CAD deficiency: an epileptic encephalopathy treatable with uridine supplementation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Underlying pathogenic variants are often rated as variants of unknown significance, which could lead to underrecognition of this treatable disorder."
    explanation: >-
      States the clinical consequence of the interpretation problem, which is
      the reason this is worth recording in a knowledge base at all.
  - reference: PMID:37984840
    reference_title: "Biallelic hypomorphic variants in CAD cause uridine-responsive macrocytic anaemia with elevated haemoglobin-A2."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Functional studies did not support complete abrogation of protein function; however, the patient responded to uridine supplement. We conclude that biallelic hypomorphic CAD variants may cause a primarily haematological phenotype."
    explanation: >-
      Establishes the hypomorphic allelic class and its distinct phenotypic
      consequence.
  - reference: PMID:38454370
    reference_title: "Novel CAD gene mutations in a boy with developmental and epileptic encephalopathy 50 with dramatic response to uridine therapy: a case report and a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "revealed a compound heterozygous variant in the CAD gene, with one locus inherited from his father (c.1252C>T: p.Q418* nonsense mutation) and one from his mother (c.6628G>A: p.G2210S, missense mutation)"
    explanation: >-
      A worked example of the compound-heterozygous nonsense-plus-missense
      genotype typical of the disorder.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    Forty-two patients had been reported in the literature as of the 2024
    review, which is that publication's own pooled count. Cases have appeared
    since, so 42 is a dated lower bound rather than a current total. No
    population prevalence has been estimated, and the authors' own point is that
    the true figure is likely higher because pathogenic variants are commonly
    misfiled as variants of unknown significance.
  evidence:
  - reference: PMID:38454370
    reference_title: "Novel CAD gene mutations in a boy with developmental and epileptic encephalopathy 50 with dramatic response to uridine therapy: a case report and a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "To date, 42 cases of CAD variants have been reported"
    explanation: >-
      The explicit literature count, kept as a count rather than converted into
      a population rate.
progression:
- phase: Onset
  notes: >-
    Onset is early. Ninety per cent of reported patients presented before three
    years of age, at a mean of about 1.6 years, and of those with seizures 76%
    began before age two. Neonatal-onset presentations occur.
  evidence:
  - reference: PMID:38454370
    reference_title: "Novel CAD gene mutations in a boy with developmental and epileptic encephalopathy 50 with dramatic response to uridine therapy: a case report and a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among them, 90% had onset before 3 years of age, with average of 1.6±1.8 years old."
    explanation: >-
      The onset distribution from the pooled review.
  - reference: PMID:32820246
    reference_title: "Expanding the clinical and genetic spectrum of CAD deficiency: an epileptic encephalopathy treatable with uridine supplementation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "add that milder courses with isolated developmental delay/intellectual disability can occur as well as onset with neonatal seizures"
    explanation: >-
      Extends the onset range at both ends — neonatal seizures, and milder
      later-recognized courses.
- phase: Diagnostic delay
  notes: >-
    There is a large gap between onset and diagnosis: a mean age at diagnosis of
    7.7 years against a mean onset of 1.6 years, with a range extending to 43
    years. Because the disorder is treatable and untreated patients deteriorate,
    this delay is itself a determinant of outcome.
  evidence:
  - reference: PMID:38454370
    reference_title: "Novel CAD gene mutations in a boy with developmental and epileptic encephalopathy 50 with dramatic response to uridine therapy: a case report and a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The age at diagnosis was 7.7 ± 10 years on average (school age) and ranged from 9 months to 43 years with a median of 5.5 years, only two cases were diagnosed in adult."
    explanation: >-
      Quantifies the diagnostic delay against the onset figures above.
- phase: Untreated course and mortality
  notes: >-
    Untreated, the disease is progressive and can be lethal in early childhood.
    The pooled mortality was about 9.5%, and every reported death was in a
    patient who had not received uridine — the single most consequential
    observation in the literature on this disorder.
  evidence:
  - reference: PMID:38454370
    reference_title: "Novel CAD gene mutations in a boy with developmental and epileptic encephalopathy 50 with dramatic response to uridine therapy: a case report and a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The mortality rate was approximately 9.5%, with all reported deaths occurring in patients without uridine treatment."
    explanation: >-
      The mortality figure together with its association with untreated status.
  - reference: PMID:28007989
    reference_title: "CAD mutations and uridine-responsive epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Two died aged 4 and 5 years after a neurodegenerative disease course."
    explanation: >-
      The founding cohort's two deaths, both untreated, establishing the lethal
      natural history.
- phase: Treated course
  notes: >-
    Response to uridine can be rapid and substantial. In the founding cohort
    seizures ceased immediately in both treated children, and a four-year-old
    previously in a minimally conscious state began to communicate and walk with
    assistance within nine weeks. Response is not uniform: a sibling started at
    14 years had only a modest response where his sister started at 5 had a
    dramatic one, which is the clearest available signal that timing matters.
  evidence:
  - reference: PMID:28007989
    reference_title: "CAD mutations and uridine-responsive epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Supplementation of the two surviving children with oral uridine led to immediate cessation of seizures in both. A 4-year-old female, previously in a minimally conscious state, began to communicate and walk with assistance after 9 weeks of treatment."
    explanation: >-
      The founding treatment observation, with its timescale.
  - reference: PMID:33497533
    reference_title: "Uridine-responsive epileptic encephalopathy due to inherited variants in CAD: A Tale of Two Siblings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Her older brother had a more severe course and only modest response to uridine started at 14 years old."
    explanation: >-
      The within-family contrast that supports treatment timing as a determinant
      of response.
diagnosis:
- name: Exome sequencing with functional validation
  description: >-
    Diagnosis rests on sequencing, but sequencing alone is not sufficient.
    Because CAD is large and prediction tools perform poorly on it, candidate
    variants are commonly returned as variants of unknown significance;
    functional validation in patient-derived fibroblasts, or in the CAD-knockout
    complementation assay, is what establishes the diagnosis. The assay is a
    CRISPR-generated human CAD-knockout line that cannot grow without uridine
    and is rescued by transfection with functional recombinant CAD.
  diagnosis_term:
    preferred_term: whole exome sequencing
    term:
      id: NCIT:C101295
      label: Whole Exome Sequencing
  evidence:
  - reference: PMID:32820246
    reference_title: "Expanding the clinical and genetic spectrum of CAD deficiency: an epileptic encephalopathy treatable with uridine supplementation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "With no biomarker available, the diagnosis relies on genetic testing and functional validation in patient-derived fibroblasts."
    explanation: >-
      States the diagnostic pathway and, critically, the absence of a metabolic
      biomarker.
  - reference: PMID:32461667
    reference_title: "Cell-based analysis of CAD variants identifies individuals likely to benefit from uridine therapy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Using CRISPR/Cas9, we generated a human CAD-knockout cell line that requires uridine supplements for survival. Transient transfection of the knockout cells with recombinant CAD restores growth in absence of uridine."
    explanation: >-
      Describes the complementation assay that resolves variants of unknown
      significance.
- name: Peripheral blood film
  description: >-
    A blood film showing anisopoikilocytosis alongside anaemia, in a child with
    developmental delay and seizures, is the routine finding most likely to
    raise the diagnosis. It is not specific and is not a biomarker in the
    metabolic sense, but it is available everywhere and normalizes on treatment,
    so it doubles as a response measure.
  evidence:
  - reference: PMID:32117025
    reference_title: "A Patient With CAD Deficiency Responsive to Uridine and Literature Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "all presented with DD, drug-resistant epilepsy, and anemia with anisopoikilocytosis"
    explanation: >-
      Establishes the triad in which the film finding is diagnostically useful.
  - reference: PMID:28007989
    reference_title: "CAD mutations and uridine-responsive epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Blood smears normalized and anaemia resolved."
    explanation: >-
      Supports the use of the film as a treatment-response readout.
treatments:
- name: Oral uridine supplementation
  description: >-
    Uridine bypasses the enzymatic block by entering the pyrimidine pool through
    the salvage route, which does not require CAD. It is given as uridine,
    uridine monophosphate or uridine triacetate. In treated patients seizures
    can stop immediately, development resumes, cerebellar atrophy can arrest and
    the blood film normalizes; supplementation was safe in the largest treated
    series. The disorder's authors recommend a trial in any patient with
    developmental delay, epilepsy and anaemia, in any patient with status
    epilepticus, and in any patient with neonatal seizures, until the diagnosis
    is excluded or six months have passed without benefit — an unusually
    permissive threshold that follows from the treatment's safety and the
    untreated mortality.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: uridine
      term:
        id: CHEBI:16704
        label: uridine
    - preferred_term: uridine triacetate
      term:
        id: CHEBI:90914
        label: uridine triacetate
  target_mechanisms:
  - target: Intact Uridine Salvage Pathway
    treatment_effect: ACTIVATES
    description: >-
      Supplying exogenous uridine drives the CAD-independent salvage route,
      which is the node this treatment acts through.
  - target: Pyrimidine Nucleotide and UDP-Sugar Pool Depletion
    treatment_effect: BYPASSES
    description: >-
      The depleted nucleotide and UDP-sugar pools are refilled without
      restoring CAD activity, which is why a complete enzymatic loss is still
      treatable.
  target_phenotypes:
  - preferred_term: Epileptic encephalopathy
    term:
      id: HP:0200134
      label: Epileptic encephalopathy
  - preferred_term: Anemia
    term:
      id: HP:0001903
      label: Anemia
  evidence:
  - reference: PMID:28007989
    reference_title: "CAD mutations and uridine-responsive epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Supplementation of the two surviving children with oral uridine led to immediate cessation of seizures in both."
    explanation: >-
      The founding demonstration of efficacy on the seizure endpoint.
  - reference: PMID:25678555
    reference_title: "Biallelic mutations in CAD, impair de novo pyrimidine biosynthesis and decrease glycosylation precursors."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Uridine supplementation rescued these abnormalities, suggesting a potential therapy for this new glycosylation disorder."
    explanation: >-
      The biochemical basis of the treatment — correction of the depleted pools
      in patient cells — which is the mechanism the target_mechanisms links
      record.
  - reference: PMID:32820246
    reference_title: "Expanding the clinical and genetic spectrum of CAD deficiency: an epileptic encephalopathy treatable with uridine supplementation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Supplementation with uridine, uridine monophosphate, or uridine triacetate in ten patients was safe and led to significant clinical improvement in most patients."
    explanation: >-
      The largest treated series, establishing safety and the three acceptable
      preparations, with the qualifier that improvement was in most rather than
      all.
  - reference: PMID:32820246
    reference_title: "Expanding the clinical and genetic spectrum of CAD deficiency: an epileptic encephalopathy treatable with uridine supplementation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We advise a trial with uridine (monophosphate) in all patients with developmental delay/intellectual disability, epilepsy, and anemia; all patients with status epilepticus; and all patients with neonatal seizures until (genetically) proven otherwise or proven unsuccessful after 6 months."
    explanation: >-
      The empirical-trial recommendation and its stopping rule, quoted in full
      so the threshold is not overstated.
  notes: >-
    Evidence is from case series and cohort reports; no randomized trial exists
    and none is likely at this cohort size. The recommendation to trial uridine
    empirically rests on safety plus untreated mortality, not on controlled
    comparison.
animal_models:
- name: CAD-deficient Bengal cat
  species: Cat
  genotype: CAD p.Ser2015Asn homozygous
  category: Genetic
  description: >-
    A naturally occurring feline model. A four-month-old Bengal kitten with
    intractable seizures and abnormal behaviour carried a homozygous CAD variant
    predicted to disrupt oligomerization of the C-terminal ATCase domain, and
    the variant failed to rescue growth in the human CAD-knockout complementation
    assay. Four further carriers were found among 110 unaffected Bengals, so the
    allele segregates in the breed. This is a spontaneous large-animal model of
    a disorder whose human cohort is only a few dozen people.
  publication: PMID:40251393
  genes:
  - preferred_term: CAD
    term:
      id: hgnc:1424
      label: CAD
  modeled_mechanisms:
  - target: Biallelic CAD Loss of Function
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      The feline variant abolishes CAD function in the same complementation
      assay used to classify human variants, and the affected kitten had
      intractable seizures.
    limitations: >-
      A single affected animal, characterized clinically rather than
      neuropathologically; the haematological arm of the human phenotype was not
      reported, and no uridine trial was performed, so the model's treatment
      responsiveness is inferred rather than demonstrated.
    readouts:
    - name: Growth rescue of CAD-knockout cells by the feline variant
      target: Biallelic CAD Loss of Function
      direction: ABOLISHED
      interpretation: >-
        The mutant protein cannot support growth without uridine, establishing
        loss of function rather than a benign substitution.
      evidence:
      - reference: PMID:40251393
        reference_title: "Epileptic encephalopathy in a young Bengal cat caused by CAD deficiency."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "In a CAD-knockout human cell line dependent on uridine, the recombinant expression of human wildtype CAD, but not of the Asn2015 mutant, restored cell growth without uridine, demonstrating that the p.Ser2015Asn variant disrupts CAD function and is pathogenic."
        explanation: >-
          The functional measurement and its direction.
    evidence:
    - reference: PMID:40251393
      reference_title: "Epileptic encephalopathy in a young Bengal cat caused by CAD deficiency."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Here, we report a novel variant in the feline CAD gene in a 4-month-old Bengal kitten with intractable seizures and abnormal behavior."
      explanation: >-
        Establishes the model as an informative naturally occurring counterpart
        of the human trigger lesion.
  evidence:
  - reference: PMID:40251393
    reference_title: "Epileptic encephalopathy in a young Bengal cat caused by CAD deficiency."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "CAD-deficient Bengal cats might serve as a valuable spontaneous large animal model to further investigate the pathogenic mechanisms of this rare epileptic encephalopathy in humans."
    explanation: >-
      The authors' own framing of the animal as a model for the human disease,
      quoted with the hedge they used.
experimental_models:
- name: CRISPR CAD-knockout human cell line
  description: >-
    A CRISPR/Cas9-generated human CAD-knockout line that cannot grow without
    uridine and is rescued by transfection with functional recombinant CAD. It
    is simultaneously the disease model and the diagnostic assay: growth rescue
    is the readout that classifies a patient variant as tolerated or deleterious,
    and therefore predicts who will benefit from uridine.
  experimental_model_type: CELL_LINE
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  publication: PMID:32461667
  modeled_mechanisms:
  - target: Biallelic CAD Loss of Function
    relationship: RECAPITULATES
    fidelity: HIGH
    description: >-
      A complete CAD knockout reproduces the defining cellular consequence of
      the human lesion: uridine dependence for survival.
    limitations: >-
      A proliferating immortalized line is the compartment in which de novo
      synthesis matters most, so it models the metabolic lesion well and the
      neuronal consequence not at all. It also reports total loss rather than
      the graded residual activity of hypomorphic alleles.
    readouts:
    - name: Growth without uridine supplementation
      target: Biallelic CAD Loss of Function
      direction: ABOLISHED
      interpretation: >-
        Loss of CAD makes the cell line dependent on exogenous uridine, which is
        the cellular phenotype the disease and its treatment both turn on.
      evidence:
      - reference: PMID:32461667
        reference_title: "Cell-based analysis of CAD variants identifies individuals likely to benefit from uridine therapy."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "we generated a human CAD-knockout cell line that requires uridine supplements for survival"
        explanation: >-
          The measurement and its direction.
    evidence:
    - reference: PMID:32461667
      reference_title: "Cell-based analysis of CAD variants identifies individuals likely to benefit from uridine therapy."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Transient transfection of the knockout cells with recombinant CAD restores growth in absence of uridine. This system determines missense variants that inactivate CAD and do not rescue the growth phenotype."
      explanation: >-
        Establishes the rescue logic that makes the line informative for the
        trigger node.
  evidence:
  - reference: PMID:32461667
    reference_title: "Cell-based analysis of CAD variants identifies individuals likely to benefit from uridine therapy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "We designed a cell-based assay to test the pathogenicity of CAD variants, identifying 11 CAD-deficient individuals who could benefit from uridine therapy."
    explanation: >-
      Establishes the system as informative for the disease and its direct
      clinical use.
- name: Patient-derived dermal fibroblasts
  description: >-
    Fibroblasts from affected individuals carry the biochemical lesion and are
    the system in which it was first characterized: impaired aspartate
    incorporation into RNA and DNA by the de novo route, depleted CTP, UTP and
    UDP-sugars, and correction of all of it by uridine.
  experimental_model_type: PRIMARY_CELL_CULTURE
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  cell_types:
  - preferred_term: Dermal fibroblast
    term:
      id: CL:0002620
      label: skin fibroblast
  publication: PMID:25678555
  modeled_mechanisms:
  - target: Pyrimidine Nucleotide and UDP-Sugar Pool Depletion
    relationship: MEASURES
    fidelity: HIGH
    description: >-
      Direct quantification of the depleted nucleotide and UDP-sugar pools in
      human patient cells, with uridine rescue.
    limitations: >-
      Fibroblasts are not an affected tissue; they report the cell-autonomous
      metabolic lesion but say nothing about why neurons and erythroid
      precursors specifically are damaged.
    readouts:
    - name: CTP, UTP and UDP-activated sugar levels
      target: Pyrimidine Nucleotide and UDP-Sugar Pool Depletion
      direction: DECREASED
      interpretation: >-
        Confirms in human cells that the block depletes both the nucleotide
        pool and the glycosylation donor pool.
      evidence:
      - reference: PMID:25678555
        reference_title: "Biallelic mutations in CAD, impair de novo pyrimidine biosynthesis and decrease glycosylation precursors."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: "CTP, UTP and nearly all UDP-activated sugars that serve as donors for glycosylation were decreased."
        explanation: >-
          The measurement and its direction.
    evidence:
    - reference: PMID:25678555
      reference_title: "Biallelic mutations in CAD, impair de novo pyrimidine biosynthesis and decrease glycosylation precursors."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "Metabolic flux studies showed impaired aspartate incorporation into RNA and DNA through the de novo synthesis pathway."
      explanation: >-
        Establishes the system as carrying the disease biochemistry.
  evidence:
  - reference: PMID:32820246
    reference_title: "Expanding the clinical and genetic spectrum of CAD deficiency: an epileptic encephalopathy treatable with uridine supplementation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the diagnosis relies on genetic testing and functional validation in patient-derived fibroblasts"
    explanation: >-
      Establishes that this system is not merely a research model but part of
      the diagnostic pathway.
differential_diagnoses:
- name: DTYMK-related neurodegeneration
  description: >-
    The other neurodegenerative disorder of the pyrimidine pathway, and the
    instructive contrast. DTYMK sits downstream of the point at which the de
    novo and salvage routes converge, so its loss cannot be bypassed and uridine
    is not a rational therapy — whereas CAD sits at the entry to the pathway, so
    it can. The two are already cross-referenced from the DTYMK entry in this
    knowledge base.
  notes: >-
    No evidence item is attached: the claim recorded here is the pathway-position
    contrast, which is asserted in the DTYMK entry with its own evidence rather
    than re-derived here.
discussions:
- discussion_id: gap_pyrimidine_depletion_to_neuronal_injury
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    By what route does depletion of pyrimidine nucleotides and UDP-sugars
    produce neuronal injury, seizures and brain atrophy, rather than a uniform
    proliferation defect?
  attaches_to:
  - "pathophysiology#Pyrimidine Nucleotide and UDP-Sugar Pool Depletion"
  - "pathophysiology#Progressive Neuronal Injury and Brain Atrophy"
  rationale: >-
    The metabolic lesion is measured directly in patient fibroblasts and the
    clinical endpoint is well described, but nothing in between is. Proposed
    routes include impaired glycosylation of neuronal proteins, since UDP-sugar
    donors are depleted, and impaired nucleic acid synthesis during neuronal
    differentiation; neither has been demonstrated in neural tissue from an
    affected individual or a model. The gap matters practically: it is why there
    is no biomarker of neuronal involvement, and why treatment response is
    monitored with seizure counts and blood films rather than anything
    mechanism-specific.
  proposed_experiments:
  - experiment_id: exp_neuronal_glycosylation_in_cad_deficiency
    name: Glycosylation and nucleotide status in CAD-deficient neurons
    description: >-
      Differentiate neurons from a CAD-deficient patient iPSC line (one already
      exists) alongside isogenic controls, and measure UDP-sugar pools, protein
      glycosylation and neurite outgrowth with and without uridine. A
      glycosylation deficit correcting on uridine would support the
      glycosylation route; a normal glycan profile with impaired outgrowth would
      point at the nucleic-acid-synthesis route instead.
  evidence:
  - reference: PMID:32820246
    reference_title: "Expanding the clinical and genetic spectrum of CAD deficiency: an epileptic encephalopathy treatable with uridine supplementation."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "With no biomarker available, the diagnosis relies on genetic testing and functional validation in patient-derived fibroblasts."
    explanation: >-
      The absence of a biomarker is the practical face of this gap — no measured
      quantity tracks the neuronal arm of the disease.
- discussion_id: gap_treatment_timing_and_reversibility
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    How much of the neurological damage in CAD deficiency is reversible, and
    does the answer depend on age at which uridine is started?
  attaches_to:
  - "pathophysiology#Progressive Neuronal Injury and Brain Atrophy"
  rationale: >-
    The evidence that timing matters is real but thin: one sibling pair in which
    the younger sib treated at 5 improved dramatically and the older treated at
    14 only modestly. That is a single family, and severity and age are
    confounded within it — the brother is described as having had a more severe
    course independently of when he was treated. The question is consequential
    because it is the argument for newborn screening, which the founding study
    and the largest series both raise.
  proposed_experiments:
  - experiment_id: exp_age_stratified_uridine_response
    name: Age-stratified outcome registry
    description: >-
      Pool treated patients across centres and relate response — seizure
      freedom, developmental trajectory, arrest of atrophy on serial MRI — to
      age at treatment initiation and to pre-treatment severity separately, so
      the two can be disentangled. At the current cohort size this needs
      international pooling rather than a single series.
  evidence:
  - reference: PMID:33497533
    reference_title: "Uridine-responsive epileptic encephalopathy due to inherited variants in CAD: A Tale of Two Siblings."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Her older brother had a more severe course and only modest response to uridine started at 14 years old."
    explanation: >-
      Classified PARTIAL: the observation is consistent with a timing effect but
      confounds it with baseline severity, which is exactly the ambiguity the
      proposed experiment is meant to resolve.
notes: >-
  Deliberate non-conformances. This entry does not declare conformance to
  epilepsy_excitation_inhibition_imbalance: that module runs through a measured
  excitation-inhibition imbalance, and no such measurement exists in CAD
  deficiency, so conforming would substitute a plausible route for an evidenced
  one. It likewise does not conform to cerebellar_purkinje_degeneration —
  cerebellar atrophy here is an imaging finding in 4 of 24 imaged patients, with
  no Purkinje-cell-specific lesion demonstrated. Both decisions are recorded so
  a later curator with new evidence knows what would need to change.

  Frequency bands are taken only from the 2024 pooled review, which reports each
  figure against an explicit denominator of 42 patients (or 19 and 24 for the
  extrapyramidal and imaging subsets). Phenotypes described only in single case
  reports carry no band.

  A note on this entry's deep-research report. Its own reference validation set
  `needs_review: true` with 4 of 9 quoted claims unsupported, despite a
  confabulation rate of 0.0 — the identifiers all resolved, the quotes did not
  match. No snippet in this entry was taken from that report; every one was
  read out of the cached reference. Five of the report's suggested ontology
  terms were also wrong, among them GO:0004087, which is the ammonia-dependent
  carbamoyl-phosphate synthetase of the urea cycle rather than CAD's
  glutamine-hydrolyzing CPS-II — a substitution that would have asserted the
  wrong enzyme. The bound term is GO:0004088.

  Review round on PR #9391. Three of the reviewer's six optional suggestions
  were applied: strabismus (7%) was added as a phenotype from the same
  denominator-bearing sentence already quoted elsewhere; uridine triacetate was
  added as a second `therapeutic_agent`; and an NCIT binding was added to the
  exome-sequencing diagnosis entry. Three were declined, with reasons. (An
  earlier draft of this paragraph said "both diagnosis entries"; only one was
  bound, for the reason given below.)

  The suggestion to curate uridine triacetate's reported four-to-six-fold
  bioavailability advantage was declined because no quotable source for it
  exists here. The review attributed the figure to "Frederick et al. 2021,
  already cited as PMID:33497533", but PMID:33497533 is McGraw et al., "A Tale
  of Two Siblings", and its cached record contains no bioavailability statement.
  The agent is therefore curated by identity (CHEBI:90914) without the
  pharmacokinetic claim.

  The review also relayed the deep-research report's suggestion of NCIT:C17004
  for whole exome sequencing. That term is Genetic Polymorphism. The binding
  used is NCIT:C101295, verified against OLS4 — the third instance in this entry
  of a suggested term being wrong, and the reason every term here was checked
  individually rather than accepted. The peripheral blood film was left unbound:
  NCIT:C79903 Blood Smear is not reachable from NCIT:C25218 (Clinical
  Intervention or Procedure), so it fails the TreatmentActionTerm enum, and no
  reachable term names the assay. Leaving it unbound is preferred to binding a
  broader procedure term that would not mean "blood film".

  `evidence_source: OTHER` was retained on the two PMID:34288185 items. The
  suggestion to consider IN_VITRO is reasonable, but that reference is a review
  article and the statements cited from it are descriptive summaries of protein
  architecture rather than experiments it performed, which is what OTHER is for.

  No `datasets:` block: the mechanistic work on this disorder is targeted
  nucleotide and UDP-sugar quantification in patient fibroblasts rather than
  deposited omics, and no disease-specific dataset was identified.
references:
- reference: PMID:28007989
  title: "CAD mutations and uridine-responsive epileptic encephalopathy."
- reference: PMID:25678555
  title: "Biallelic mutations in CAD, impair de novo pyrimidine biosynthesis and decrease glycosylation precursors."
- reference: PMID:32820246
  title: "Expanding the clinical and genetic spectrum of CAD deficiency: an epileptic encephalopathy treatable with uridine supplementation."
- reference: PMID:32461667
  title: "Cell-based analysis of CAD variants identifies individuals likely to benefit from uridine therapy."
- reference: PMID:38454370
  title: "Novel CAD gene mutations in a boy with developmental and epileptic encephalopathy 50 with dramatic response to uridine therapy: a case report and a review of the literature."
- reference: PMID:33497533
  title: "Uridine-responsive epileptic encephalopathy due to inherited variants in CAD: A Tale of Two Siblings."
- reference: PMID:32117025
  title: "A Patient With CAD Deficiency Responsive to Uridine and Literature Review."
- reference: PMID:37984840
  title: "Biallelic hypomorphic variants in CAD cause uridine-responsive macrocytic anaemia with elevated haemoglobin-A2."
- reference: PMID:34288185
  title: "Deciphering CAD: Structure and function of a mega-enzymatic pyrimidine factory in health and disease."
- reference: PMID:40251393
  title: "Epileptic encephalopathy in a young Bengal cat caused by CAD deficiency."

📚

References & Deep Research

References

10

PMID:28007989

CAD mutations and uridine-responsive epileptic encephalopathy.

No top-level findings curated for this source.

PMID:25678555

Biallelic mutations in CAD, impair de novo pyrimidine biosynthesis and decrease glycosylation precursors.

No top-level findings curated for this source.

PMID:32820246

Expanding the clinical and genetic spectrum of CAD deficiency: an epileptic encephalopathy treatable with uridine supplementation.

No top-level findings curated for this source.

PMID:32461667

Cell-based analysis of CAD variants identifies individuals likely to benefit from uridine therapy.

No top-level findings curated for this source.

PMID:38454370

Novel CAD gene mutations in a boy with developmental and epileptic encephalopathy 50 with dramatic response to uridine therapy: a case report and a review of the literature.

No top-level findings curated for this source.

PMID:33497533

Uridine-responsive epileptic encephalopathy due to inherited variants in CAD: A Tale of Two Siblings.

No top-level findings curated for this source.

PMID:32117025

A Patient With CAD Deficiency Responsive to Uridine and Literature Review.

No top-level findings curated for this source.

PMID:37984840

Biallelic hypomorphic variants in CAD cause uridine-responsive macrocytic anaemia with elevated haemoglobin-A2.

No top-level findings curated for this source.

PMID:34288185

Deciphering CAD: Structure and function of a mega-enzymatic pyrimidine factory in health and disease.

No top-level findings curated for this source.

PMID:40251393

Epileptic encephalopathy in a young Bengal cat caused by CAD deficiency.

No top-level findings curated for this source.

Deep Research

1

Claude Code ▸

Developmental and Epileptic Encephalopathy 50 (DEE50 / CAD Deficiency): Comprehensive Research Report

claude-haiku-4-5-20251001, claude-sonnet-5 15 citations 2026-08-24T15:53:41.355869

Developmental and Epileptic Encephalopathy 50 (DEE50 / CAD Deficiency): Comprehensive Research Report

1. Disease Information

Overview. Developmental and Epileptic Encephalopathy 50 (DEE50), also known as Early Infantile Epileptic Encephalopathy-50 (EIEE50) or CAD deficiency, is an ultra-rare autosomal recessive inborn error of pyrimidine de novo biosynthesis. It is caused by biallelic (homozygous or compound heterozygous) loss-of-function or hypomorphic variants in the CAD gene (chromosome 2p23.3), which encodes the trifunctional/tetrafunctional enzyme catalyzing the first three (some sources say four, counting the glutaminase domain) steps of pyrimidine synthesis. The disease is characterized by early-onset, drug-refractory epilepsy, global developmental delay/regression, dyserythropoietic (typically macrocytic or normocytic) anemia with anisopoikilocytosis, and progressive brain atrophy — but it is one of the relatively few genetic epileptic encephalopathies that is directly and often dramatically treatable with exogenous uridine, which bypasses the metabolic block via the pyrimidine salvage pathway (Koch et al., Brain 2017, PMID: 28007989; case report/review, PMC10921618).

Key identifiers: | Resource | ID | |---|---| | OMIM | #616457 | | MedGen | UID 904125 / UMLS C4225320 | | Monarch/Mondo | MONDO:0014647 | | Orphanet | ORPHA448010 | | Gene (CAD) | HGNC:1424; chr2p23.3; NCBI Gene ID 790 | | Disease Ontology | DOID:0080419 |

Synonyms: Early Infantile Epileptic Encephalopathy 50 (EIEE50); CAD deficiency; CAD-CDG (when framed as a congenital disorder of glycosylation, since UDP-sugar donors are also depleted).

Data provenance: Because DEE50 is extremely rare (approximately 40–50 molecularly confirmed patients reported worldwide as of 2024–2025), the evidence base is derived almost entirely from aggregated case reports and small case series (individual families identified by exome/genome sequencing) rather than large-cohort EHR or registry data — i.e., this is a "disease-level resource" literature, built up patient-by-patient since the first description in 2015.

Source: OMIM #616457, MedGen DEE50, Malacards DEE50

2. Etiology

Disease Causal Factors

DEE50 is monogenic, caused exclusively by biallelic pathogenic variants in CAD. There is no known environmental, infectious, or purely mechanistic (non-genetic) cause. The gene product is essential for the first steps of de novo pyrimidine nucleotide synthesis; loss of activity produces a cellular pyrimidine (UMP/UTP/CTP) and UDP-sugar deficit that is particularly damaging to the developing nervous system and erythropoiesis.

Risk Factors

Genetic: Biallelic CAD variants are necessary and sufficient. Consanguinity substantially raises risk in affected families — the literature review by PMC10921618 found 5 of 42 published cases had consanguineous parents, and 12 had a positive family history. A founder mutation (p.Met33Arg) was identified in unrelated Serbian Roma families in the original description (Koch et al. 2017), consistent with an ethnically enriched allele in that population.
Environmental: None established; this is a purely genetic/metabolic disease.
Sex: No sex-linked susceptibility (autosomal recessive); however, the "Tale of Two Siblings" report (PMC7951104) noted an affected brother had an earlier and more severe course than his affected sister despite identical genotype — attributed to earlier diagnosis/treatment timing rather than sex per se.

Protective Factors

Genetic: None specific (a wild-type or hypomorphic-but-functional CAD allele on at least one chromosome is fully protective — heterozygous carriers are asymptomatic).
Environmental: Dietary/exogenous pyrimidine (uridine) intake is the key modifiable protective/therapeutic factor, since it engages the salvage pathway independent of the defective de novo route.

Gene-Environment Interactions

The core "interaction" in this disease is pharmacogenomic rather than classically environmental: CAD-deficient cells cannot synthesize sufficient pyrimidines de novo, but retain an intact salvage pathway (uridine kinase/UMP synthase route), so exogenous dietary uridine supplementation functionally substitutes for the genetic lesion. Cell-based functional assays (Genetics in Medicine 2020, PMID: 32117025-adjacent work, "Cell-based analysis of CAD variants identifies individuals likely to benefit from uridine therapy") explicitly test which variants retain enough salvage-pathway responsiveness to predict clinical benefit — a genotype-driven precision-therapy interaction.

Suggested ontology terms: MONDO:0014647 (disease); HGNC:1424 (gene); GO:0006207 (‘de novo’ pyrimidine nucleobase biosynthetic process).

3. Phenotypes

DEE50 phenotypes cluster into neurological, hematological, and (less consistently) systemic/metabolic domains. Frequencies below are drawn from the pooled literature review of 42 published cases (PMC10921618) unless otherwise cited.

Neurological / Developmental

Phenotype	Frequency	HPO term (suggested)
Global developmental delay / regression	95%	HP:0011344 (Progressive developmental regression) / HP:0001263 (Global developmental delay)
Refractory/drug-resistant epilepsy	73% (of the cohort); 64% of those with epilepsy were drug-refractory	HP:0011451 (Drug-resistant epilepsy)
Focal seizures	41% of seizure cases	HP:0007359 (Focal-onset seizure)
Generalized tonic-clonic seizures	37%	HP:0002069 (Bilateral tonic-clonic seizure)
Myoclonic seizures	8%	HP:0032794 (Myoclonic seizure)
Status epilepticus	45% of epilepsy cases	HP:0002133 (Status epilepticus)
Heat-sensitive seizures	13%	HP:0011175 (Fever-induced seizure descriptors)
Ataxia	73% of extrapyramidal cases	HP:0001251 (Ataxia)
Tremor	36%	HP:0001337 (Tremor)
Hypotonia	14%	HP:0001252 (Hypotonia)
Dysphagia	23%	HP:0002015 (Dysphagia)
Gait abnormality	26%	HP:0001288 (Gait disturbance)
Extrapyramidal/movement disorder (general)	33%	HP:0002071 (Abnormality of extrapyramidal motor function)

Onset: Mean age of first symptoms 1.6 ± 1.8 years; 90% before age 3; some neonatal-onset cases (3/42) and a spectrum extending to milder, later-onset isolated developmental delay/intellectual disability (Rymen et al., Genetics in Medicine 2021, "Expanding the clinical and genetic spectrum of CAD deficiency," PMID search via GIM/ScienceDirect S1098360021007607).
Severity/progression: Progressive and, if untreated, can be lethal in early childhood (Koch et al. 2017 abstract: "the natural disease course can be lethal in early childhood"). With uridine treatment the course is frequently arrested or reversed.
Diagnostic lag: Mean age at diagnosis 7.7 ± 10 years vs. mean onset 1.6 years — a roughly 6-year diagnostic delay, reflecting the rarity and non-specific early presentation.

Hematological

Phenotype	Frequency	HPO term
Anemia (typically macrocytic or normocytic; occasionally microcytic hypochromic)	71%	HP:0001903 (Anemia)
Anisocytosis / poikilocytosis (target cells, teardrop cells, acanthocytes)	present in ~1/3 with detailed morphology reported	HP:0011273 (Anisopoikilocytosis)
Dyserythropoiesis	reported in original Koch et al. cohort	HP:0012156 (dyserythropoiesis-adjacent term)
Elevated hemoglobin A2 (in the hypomorphic/milder allelic series)	isolated report	—

A distinct, milder allelic presentation was described in 2023: biallelic hypomorphic CAD variants causing uridine-responsive macrocytic anemia with elevated hemoglobin-A2 and only mild developmental delay, without epileptic encephalopathy — demonstrating that CAD deficiency is a phenotypic continuum from a primarily hematologic disorder to the classic severe DEE (Br J Haematol 2023, PMID: 37984840).

Other systemic/metabolic phenotypes (from MedGen clinical synopsis)

Failure to thrive (HP:0001508)
Orotic aciduria (HP:0003132) — reflects downstream metabolic consequences
Hyperammonemia (HP:0001987) and renal tubular acidosis (HP:0001947) — reported metabolic complications
Abnormal glycosylation (relevant to the "CAD-CDG" framing, since UDP-sugar precursors are also depleted)
Speech difficulties/absent language (HP:0002465 / HP:0001344)
Diarrhea (HP:0002014)

Neuroimaging (a semi-quantitative/imaging phenotype)

57% of cases had abnormal brain MRI; of these, 73% showed brain atrophy (29% whole-brain, 16% cerebellar), 8% hydrocephalus, 8% delayed myelination. Atrophy is progressive — one report noted cerebral/cerebellar atrophy "gradually progressed after 3.5 years of age" (PMC10921618).

Quality-of-life impact

Not formally studied with standardized instruments (no EQ-5D/SF-36 data identified for this ultra-rare disease); however, functional outcome measures (Vineland/Bayley developmental scales, Coma Recovery Scale in severely affected patients) are used descriptively in case reports to document dramatic improvement after uridine (e.g., Coma Recovery Scale improving from 5 to 16 within 2 months in one Koch et al. patient; PMC10921618 index case achieving self-feeding, eye contact, independent sitting after treatment).

Source: BMC Pediatrics case report/review (PMC10921618), MedGen DEE50, Koch et al. 2017, Brain

4. Genetic / Molecular Information

Causal Gene

Gene: CAD (carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase); HGNC:1424; NCBI Gene ID 790; chromosome 2p23.3; ~44 exons.
Protein: A single 243-kDa, 2,225-amino-acid polypeptide that self-assembles into a large (~1.5 MDa) hexameric multi-enzyme complex carrying four sequential catalytic activities: glutamine amidotransferase (GATase), carbamoyl phosphate synthetase II (CPS-II), aspartate transcarbamylase (ATCase), and dihydroorotase (DHOase). These domains "channel" reaction intermediates (notably glutamine-derived ammonia) directly between active sites without release into bulk solvent — a classic example of metabolic substrate channeling. Zinc (3 Zn²⁺/subunit) is required for DHOase activity; Mg²⁺/Mn²⁺ are cofactors for other domains.
Pathway: CAD catalyzes the first three (of six) steps of the de novo pyrimidine biosynthesis pathway, ultimately producing UMP, the precursor of all cellular pyrimidine nucleotides (UTP, CTP) and of UDP-activated sugars needed for glycosylation.

Pathogenic Variants

Variant spectrum: Across 42 reviewed cases with 80 mutation sites, missense variants predominate (78%), followed by nonsense (15%) and splice-site (6%) variants (PMC10921618).
Representative variants reported across the literature:
c.98T>G (p.Met33Arg) — homozygous founder variant in Serbian Roma families (Koch et al. 2017)
c.1843-3C>T (splice acceptor) + c.5365C>T (p.Arg1789*) — compound heterozygous (Koch et al. 2017)
c.1843-1G>A (in-frame exon 13 deletion) + c.6071G>A (p.Arg2024Gln) — compound heterozygous (Ng et al., Hum Mol Genet 2015, PMC4424951)
c.5296_5308del13 (frameshift) + c.5429G>A (p.Arg1810Gln) — sibling pair (PMC7951104)
c.1252C>T (p.Gln418*) + c.6628G>A (p.Gly2210Ser) — novel compound heterozygous variants, index case (PMC10921618)
c.2995G>A (p.Val999Met) — homozygous, novel, three affected/deceased Iranian siblings (PMC8915536)
Classification: Per ACMG/AMP framework, most reported variants are classified pathogenic or likely pathogenic on the basis of segregation, absence/rarity in population databases, and functional (cell-based) rescue assays.
Functional consequences: Predominantly loss-of-function (complete or partial); a hypomorphic allelic class exists that retains partial enzyme activity and produces a milder, primarily hematologic phenotype (Br J Haematol 2023, PMID 37984840) rather than full DEE.
Zygosity: Autosomal recessive — homozygous (often in consanguineous families or population founder-allele contexts) or compound heterozygous.
Somatic vs. germline: All reported variants are germline.
Allele frequency: Given the rarity of the disease (~40–50 published cases globally since 2015), specific gnomAD-derived carrier-frequency estimates for CAD deficiency were not identified in available resources; individual pathogenic alleles are expected to be very rare/absent in gnomAD, consistent with an ultra-rare recessive disorder, with founder-allele enrichment in specific populations (e.g., Serbian Roma for p.Met33Arg).

Modifier Genes

None specifically established; phenotypic variability (e.g., the sibling pair with identical genotype but different severity) appears attributable to age at diagnosis/treatment initiation rather than a distinct modifier locus, per the "Tale of Two Siblings" report.

Epigenetic Information

No disease-specific epigenetic (DNA methylation/histone) mechanism has been reported; DEE50 is a straightforward biallelic loss-of-function/hypomorphic Mendelian disorder.

Chromosomal Abnormalities

Not a copy-number/structural disorder; no aneuploidy, translocation, or microdeletion mechanism reported. Diagnosis is by sequence-level variant detection (trio whole-exome sequencing, WES, is the standard diagnostic route reported across case series).

Suggested ontology terms: HGNC:1424 (CAD); GO:0004070 (aspartate carbamoyltransferase activity); GO:0004087 (carbamoyl-phosphate synthase activity); GO:0004151 (dihydroorotase activity); GO:0006207 ('de novo' pyrimidine nucleobase biosynthetic process).

Source: Ng et al. 2015, Hum Mol Genet (PMC4424951), Koch et al. 2017, Brain, PMID 28007989, Br J Haematol 2023, PMID 37984840, BMC Pediatrics 2024 review (PMC10921618)

5. Environmental Information

DEE50 has no known environmental, lifestyle, or infectious causal contribution — it is a fully penetrant Mendelian metabolic disease driven by biallelic CAD variants. The only "environmental" lever of clinical relevance is therapeutic: dietary/pharmacologic uridine supplementation is not a risk-modifying exposure in the traditional sense but a disease-modifying intervention exploiting the intact salvage pathway (see Sections 2 and 12). No toxin, occupational exposure, radiation, or infectious trigger has been implicated in any published case series.

6. Mechanism / Pathophysiology

Molecular Pathway

CAD initiates the six-step de novo pyrimidine biosynthesis pathway: glutamine + HCO₃⁻ + 2ATP → carbamoyl phosphate (CPS-II domain) → carbamoyl aspartate (ATCase domain) → dihydroorotate (DHOase domain) → [downstream, via DHODH, UMPS] → orotate → OMP → UMP, the universal precursor for UTP, CTP, and (via reduction) dCTP/dTTP, as well as for UDP-sugars used in glycosylation. Suggested pathway terms: KEGG hsa00240 (Pyrimidine metabolism); Reactome R-HSA-73621 (Pyrimidine biosynthesis).

Causal Chain (Upstream → Downstream)

Upstream (molecular): Biallelic pathogenic CAD variant → loss/reduction of GATase-CPS-ATCase-DHOase enzymatic activity → failure of the first three committed steps of de novo pyrimidine synthesis.
Cellular consequence: Depletion of UMP/UTP/CTP pools and of UDP-activated sugars (UDP-glucose, UDP-galactose, etc.). Fibroblast studies from affected patients showed "reduced levels of UDP, UDP-glucose...CTP and UTP compared to control cell line" (Koch et al. 2017), and separately that "CTP, UTP and nearly all UDP-activated sugars that serve as donors for glycosylation were decreased" (Ng et al. 2015). Both defects were corrected by exogenous uridine supplementation in vitro.
Tissue/organ consequence: Pyrimidine and UDP-sugar deficiency impairs RNA/DNA synthesis and glycosylation capacity. This is proposed to particularly disrupt the neuronal differentiation process, "impair[ing] axon and dendrite formation and lead[ing] to neuronal migration disorders" (per the mechanistic synthesis in PMC10921618) — plausibly explaining the epileptogenesis, developmental regression, and progressive brain atrophy. In the erythroid lineage, impaired nucleotide/glycoconjugate synthesis produces dyserythropoiesis, anisopoikilocytosis, and anemia.
Rescue mechanism: Because the pyrimidine salvage pathway (uridine kinase → UMP synthase route) is intact and independent of CAD, exogenous uridine (or its prodrugs UMP, triacetyluridine/TAU) bypasses the defective de novo step entirely, restoring cellular UTP/CTP/UDP-sugar pools — the molecular basis for the profound clinical responsiveness described in Section 12.

Cellular Processes Involved

Nucleotide biosynthesis and salvage
Neuronal differentiation, axon/dendrite formation, neuronal migration (proposed downstream consequence of pyrimidine/glycosylation deficit)
Protein/glycan glycosylation (UDP-sugar-dependent)
Erythropoiesis (dyserythropoiesis from nucleotide deficiency)
Excitation/inhibition balance in cortical/cerebellar circuits, culminating in seizure generation and hypersynchrony (a downstream, disease-general convergence consistent with the epilepsy_excitation_inhibition_imbalance phenotype module pattern used in this knowledge base)

Protein Dysfunction

Predominantly loss-of-function (reduced/absent catalytic activity across one or more of the GATase/CPS/ATCase/DHOase domains), with a distinguishable hypomorphic class of variants that retain partial activity and produce milder, non-encephalopathic phenotypes. Structural work (e.g., "Deciphering CAD: Structure and function of a mega-enzymatic pyrimidine factory in health and disease," and crystallographic study of the DHOase domain with 5-fluorouracil) supports domain-specific functional mapping of variants (e.g., the feline p.Ser2015Asn variant disrupts ATCase-domain oligomerization).

Metabolic Changes

Depleted UTP/CTP and UDP-sugar pools (directly measured in patient fibroblasts)
Orotic aciduria has been reported as a downstream metabolic marker in some patients (HP:0003132), reflecting altered flux through the pathway
Secondary metabolic complications reported include hyperammonemia and renal tubular acidosis in some patients (per MedGen clinical synopsis)

Immune System Involvement

Not a primary feature; no autoimmune or immunodeficiency component is described in the literature reviewed.

Tissue Damage Mechanisms

Progressive brain atrophy (cerebral and cerebellar) is the dominant structural/imaging correlate of ongoing neuronal injury, consistent with cumulative nucleotide/glycosylation deficiency-driven neurodegeneration if untreated.

Molecular Profiling

Metabolomics: The principal profiling modality used to date — targeted nucleotide/UDP-sugar quantification in patient-derived fibroblasts (Ng et al. 2015; Koch et al. 2017), demonstrating both the biochemical lesion and its correction by uridine. No transcriptomic, proteomic, lipidomic, or single-cell/spatial datasets specific to DEE50 were identified in the literature searched.
Functional genomics: A dedicated cell-based functional assay platform has been developed and validated to classify patient CAD variants by residual activity/uridine-responsiveness, directly informing which patients are predicted to benefit from uridine therapy ("Cell-based analysis of CAD variants identifies individuals likely to benefit from uridine therapy," Genetics in Medicine).

Suggested ontology terms: GO:0006207 ('de novo' pyrimidine nucleobase biosynthetic process); GO:0044211 (CTP salvage); GO:0006213 (pyrimidine nucleoside metabolic process); GO:0030154 (cell differentiation, neuronal); GO:0031175 (neuron projection development); CL:0000540 (neuron); CL:0000764 (erythroid lineage cell); CHEBI:46211 (uridine).

Source: Koch et al. 2017, Brain (PMID 28007989), Ng et al. 2015, Hum Mol Genet (PMC4424951), BMC Pediatrics 2024 review (PMC10921618)

7. Anatomical Structures Affected

Organ Level

Primary: Central nervous system (cerebral cortex, cerebellum) — the dominant site of pathology (epilepsy, developmental regression, atrophy). Bone marrow/hematopoietic system — the second major site (dyserythropoiesis, anemia).
Secondary/complication-level: Kidney (renal tubular acidosis reported in some patients); gastrointestinal tract (dysphagia, diarrhea); musculoskeletal/motor system (hypotonia, gait abnormality, extrapyramidal movement disorder).
Body systems involved: Nervous system (primary), hematologic/lymphatic system (primary), and secondarily renal, gastrointestinal, and musculoskeletal systems.

Tissue and Cell Level

Nervous system: Neurons (cortical and cerebellar), consistent with cerebellar and cerebral atrophy on imaging; Purkinje cell involvement is plausible given the prominence of ataxia and cerebellar atrophy but has not been histopathologically confirmed in the literature reviewed.
Hematologic system: Erythroid precursor cells (dyserythropoiesis); mature erythrocytes show abnormal morphology (target cells, teardrop cells, acanthocytes).

Suggested Cell Ontology terms: CL:0000540 (neuron), CL:0000121 (Purkinje cell), CL:0000764 (erythroid lineage cell), CL:0000232 (erythrocyte).

Subcellular Level

The CAD enzyme complex itself is cytosolic (GO:0005737); pyrimidine biosynthesis occurs in the cytoplasm, distinct from the mitochondrially-housed pyrimidine catabolic pathway. No specific organelle pathology (mitochondrial, ER, lysosomal) has been reported as a primary disease mechanism, though downstream glycosylation defects implicate Golgi-dependent glycoconjugate processing (GO:0005794, Golgi apparatus) secondarily.

Localization

Anatomical sites (UBERON): UBERON:0000955 (brain) — specifically cerebral cortex (UBERON:0000956) and cerebellum (UBERON:0002037); UBERON:0002371 (bone marrow).
Lateralization: No lateralization pattern reported; brain atrophy is typically diffuse/bilateral (whole-brain or cerebellar), consistent with a systemic metabolic (rather than focal structural) etiology.

Source: BMC Pediatrics 2024 review (PMC10921618), MedGen DEE50

8. Temporal Development

Onset

Typical age: Mean 1.6 ± 1.8 years; 90% of cases present before age 3. A minority (3/42 in the pooled review) present in the neonatal period, and 12/42 between 1–12 months of age. A milder, later-onset spectrum (isolated developmental delay/intellectual disability without severe encephalopathy) has also been described (Rymen et al., Genetics in Medicine 2021).
Onset pattern: Typically insidious developmental delay preceding seizure onset, though some patients present acutely with status epilepticus.

Progression

Disease stages: No formal staging system exists; the clinical course is generally described as progressive neurodegeneration (developmental regression, worsening seizures, progressive brain atrophy) if untreated.
Progression rate: Variable but can be rapid — one case is described as showing "rapid deterioration of cognitive and motor function, and even became comatose" (PMC10921618).
Course pattern: Progressive/degenerative in untreated disease; can be halted or substantially reversed with uridine treatment, effectively converting the natural history from progressive-fatal to stable-or-improving.
Duration: Chronic, lifelong if untreated survival occurs; potentially fatal in early childhood without treatment (mean age at death in fatal untreated cases: 3.8 ± 1.2 years, per PMC10921618).

Patterns

Remission: Treatment-induced — seizure freedom achieved in a majority of uridine-treated patients (see Section 12), including rapid (within days) resolution of status epilepticus in some cases; no spontaneous remission is described.
Critical periods: The literature strongly suggests a critical treatment window — the sibling-pair study (PMC7951104) demonstrated that earlier uridine initiation (age 5) produced dramatic, durable improvement, whereas delayed initiation in an affected sibling (age 14) produced only modest benefit, with the authors concluding "early diagnosis leading to early treatment is more effective." This motivates calls for inclusion of CAD deficiency in expanded newborn/genetic screening panels.

Source: PMC10921618, "Tale of Two Siblings" (PMC7951104)

9. Inheritance and Population

Epidemiology

Prevalence/incidence: No formal population-based prevalence or incidence estimate exists. The disease is characterized by the total number of published/molecularly confirmed cases — approximately 40–50 patients reported globally since the disease's first description in 2015 (per the Bengal-cat animal-model paper, PMC12008240, which notes "approximately 50 CAD-deficient patients have been documented globally since 2015"). This is consistent with an ultra-rare disease.
No CDC, WHO, or GBD-level burden data exist given the extreme rarity.

Inheritance Pattern (for the genetic etiology)

Pattern: Autosomal recessive (HP:0000007).
Penetrance: Full penetrance is assumed for biallelic loss-of-function alleles based on consistent case reporting; hypomorphic alleles produce a milder, still fully penetrant but phenotypically distinct (predominantly hematologic) presentation.
Expressivity: Variable — ranging from isolated mild developmental delay/anemia (hypomorphic alleles) to severe, potentially fatal epileptic encephalopathy (classic biallelic loss-of-function). Documented intra-family variability (the affected sibling pair) further illustrates variable clinical trajectory, attributed to treatment timing rather than genotype.
Genetic anticipation: Not applicable/not reported (not a repeat-expansion disorder).
Germline mosaicism: Not specifically reported.
Founder effects: Yes — the p.Met33Arg allele was found homozygously in unrelated Serbian Roma families in the original 2017 description, consistent with a population founder effect.
Consanguinity: A notable risk factor; 5/42 reviewed cases had consanguineous parents, and the Iranian case series (PMC8915536) specifically reports a homozygous novel variant (p.Val999Met) in a family with presumed consanguinity, resulting in three affected/deceased children.
Carrier frequency: Not specifically established in population databases (gnomAD-derived estimate not identified); expected to be very low given the ultra-rare disease frequency, with population-specific enrichment where founder alleles exist.

Population Demographics

Affected populations: Reported cases span multiple ethnicities/geographies (European/Serbian Roma, Iranian, Chinese, and others), with no single predominant ethnic group apart from the Roma founder-allele cluster.
Geographic distribution: No endemic geographic clustering beyond the founder-population effect noted above; cases have been reported from Europe, the Middle East (Iran), and East Asia (China).
Sex ratio: No sex predilection is reported (autosomal recessive inheritance); both sexes are affected, as illustrated by the mixed-sex sibling pair and multiple single-sex case reports.
Age distribution: Concentrated in infancy/early childhood at diagnosis-eligible presentation, though diagnostic delay commonly extends recognition into later childhood/adolescence (mean diagnostic age 7.7 years vs. mean onset 1.6 years).

Source: PMC10921618, Koch et al. 2017 (PMID 28007989), Iranian case report (PMC8915536)

10. Diagnostics

Clinical Tests

Laboratory tests: Complete blood count with peripheral smear (revealing macrocytic or normocytic anemia with anisopoikilocytosis — target cells, teardrop cells, acanthocytes); the index case in PMC10921618 showed hemoglobin 66 g/L, RBC 3.42×10¹²/L, hematocrit 22%. Urine organic acid analysis may show orotic aciduria in some patients, though (unlike some other pyrimidine disorders) CAD deficiency does not have a universally reliable single biochemical screening marker — it is explicitly listed among treatable IMDs "for which no metabolic marker is available," prioritizing genomic sequencing in the diagnostic algorithm (per the Treatable ID App review, Orphanet J Rare Dis 2021).
Imaging: Brain MRI showing progressive cerebral and/or cerebellar atrophy, occasionally with delayed myelination or hydrocephalus.
Electrophysiology: EEG showing epileptiform/encephalopathic patterns; notably, EEG normalization has been documented after successful uridine treatment ("encephalopathic pattern disappeared," Koch et al. 2017).
Biopsy/functional studies: Patient-derived skin fibroblasts can be assayed for UTP/CTP/UDP-sugar pool depletion and for uridine-rescue response — increasingly used as a functional diagnostic/prognostic (variant-classification) tool.

Genetic Testing

Recommended approach: Because no single reliable biochemical marker exists, trio whole-exome sequencing (WES) is the diagnostic mainstay reported across essentially all published cases (Koch et al. 2017; PMC10921618; PMC8915536; PMC7951104).
WGS: Not specifically reported as the primary diagnostic modality in the literature reviewed, though it would be expected to detect the same variant classes.
Gene panels: Epilepsy/developmental-encephalopathy gene panels that include CAD would be expected to identify pathogenic variants; specific panel compositions were not detailed in sources reviewed.
Single-gene testing: Feasible once CAD is specifically suspected (e.g., in a sibling of a known proband).
Chromosomal microarray/karyotyping/FISH/mitochondrial DNA testing: Not applicable — DEE50 is a single-gene sequence-level disorder, not a copy-number or mitochondrial disease.
Repeat expansion testing: Not applicable.

Omics-Based Diagnostics

Targeted fibroblast metabolomics (UTP/CTP/UDP-sugar quantification) functions as a diagnostic-adjacent/confirmatory omics approach; no routine transcriptomic, proteomic, or liquid-biopsy diagnostic method is established for this disease.

Clinical Criteria

No formal DSM/ICD/society-specific diagnostic criteria exist for this ultra-rare disorder; diagnosis rests on the combination of the clinical triad (developmental delay/regression + refractory epilepsy + anemia with anisopoikilocytosis) plus molecular confirmation of biallelic CAD variants.

Differential diagnosis (based on overlapping phenotype: developmental and epileptic encephalopathy + anemia + treatable metabolic mechanism) should include other treatable neurometabolic DEEs — e.g., pyridoxine-dependent epilepsy, biotinidase deficiency, GLUT1 deficiency, creatine deficiency disorders, and other congenital disorders of glycosylation — since CAD deficiency is explicitly grouped among "treatable inherited metabolic disorders causing intellectual disability" in the 2021 Treatable ID App review.

Screening

CAD deficiency is not currently part of standard newborn screening panels, but multiple case reports explicitly recommend its inclusion given the availability of an effective, low-risk treatment and the severe consequences of diagnostic delay: authors of the 2024 review state "CAD should be considered to be included in neonatal genetic screening" (PMC10921618).

Suggested ontology terms: LOINC (CBC with differential, orotic acid urine test — specific LOINC codes not identified in sources reviewed); HP:0003132 (Orotic aciduria); NCIT:C17004 (Whole Exome Sequencing).

Source: PMC10921618, Treatable ID App review, Orphanet J Rare Dis 2021

11. Outcome / Prognosis

Survival and Mortality

Mortality rate: 9.5% (4 of 42 pooled cases) in the largest available literature review (PMC10921618).
Critical finding: "All reported deaths occurring in patients without uridine treatment," with mean age at death 3.8 ± 1.2 years — indicating that mortality is essentially confined to the untreated natural history, and no deaths or serious adverse events have been reported among uridine-treated patients in this dataset.
The Iranian case series (PMC8915536) independently documents three affected/deceased siblings, reinforcing that untreated/undiagnosed disease carries substantial early mortality risk, particularly before the treatable nature of the condition was recognized (pre-2017) or where diagnosis is delayed/unavailable.

Morbidity and Function

Untreated survivors accumulate progressive neurological disability: developmental regression, loss of acquired skills, worsening seizures, ataxia, dysphagia, and eventual severe functional impairment (e.g., nonverbal, tracheostomy-dependent status in the untreated/late-treated sibling in PMC7951104).
No standardized quality-of-life instrument data (EQ-5D, SF-36, PROMIS) specific to DEE50 were identified; functional improvement is instead documented via developmental testing (Bayley/Vineland-type domains: fine motor, cognition, language, social-emotional) and disease-specific functional scales (e.g., Coma Recovery Scale in severely affected patients).

Disease Course

Complications: Status epilepticus (up to 45% of epilepsy cases), aspiration risk from dysphagia, failure to thrive, and (in a subset) renal tubular acidosis/hyperammonemia.
Recovery potential: Substantial and, in several documented cases, dramatic — with treatment. Without treatment, recovery is not observed; the disease is progressive/degenerative.

Prediction

Prognostic factors: The single most consistently identified prognostic factor across the literature is age at treatment initiation — earlier uridine initiation correlates strongly with better long-term neurological outcome, as directly demonstrated in the sibling comparison (PMC7951104) and echoed by the pooled-cohort finding that all 18 treated patients in the PMC10921618 review showed favorable responses when treatment was pursued.
Prognostic biomarkers: Fibroblast-based functional assays of CAD variant activity and uridine-rescue capacity have been proposed as a means to predict which patients/genotypes are most likely to respond to therapy ("Cell-based analysis of CAD variants identifies individuals likely to benefit from uridine therapy," Genetics in Medicine).

Source: PMC10921618, "Tale of Two Siblings" PMC7951104, Iranian case report PMC8915536

12. Treatment

DEE50 is distinctive among genetic developmental and epileptic encephalopathies in having a specific, mechanism-based, highly effective disease-modifying treatment: exogenous pyrimidine (uridine) supplementation.

Pharmacotherapy — Uridine Supplementation (the primary/definitive treatment)

Three clinical formulations are reported in the literature (PMC10921618): - Uridine — ~100 mg/kg/day - Uridine monophosphate (UMP) — 141 ± 36 mg/kg/day - Uridine triacetate (triacetyluridine, TAU/Vistogard) — 110 ± 14 mg/kg/day; reported to be "four to six times more bioavailable" than plain uridine, at higher cost. A dedicated case report/review specifically evaluates triacetyluridine ("Triacetyluridine treats epileptic encephalopathy from CAD mutations: a case report and review," Frederick et al., Ann Clin Transl Neurol 2021).

Mechanism of action: Bypasses the CAD-catalyzed steps of de novo pyrimidine synthesis entirely by feeding the intact pyrimidine salvage pathway, restoring intracellular UTP/CTP and UDP-sugar pools.

Suggested NCIT term: NCIT:C15986 (Pharmacotherapy), with therapeutic_agent bound to CHEBI:46211 (uridine) or the relevant prodrug entities.

Treatment Outcomes (pooled data, PMC10921618, n=18 treated patients)

88% (16/18) showed significant developmental progress
83% (15/18) had significantly reduced seizure frequency
73% (11/18) achieved complete seizure freedom
Among 7 patients presenting with status epilepticus, all achieved seizure freedom on uridine, with three becoming seizure-free by day 2 of treatment
15/18 (83%) achieved hematologic (anemia) correction, at a mean of ~2.3 months of therapy
No deaths or serious adverse events were reported among uridine-treated patients

Illustrative individual outcomes: - Index case (PMC10921618): seizures "controlled completely" within one week of treatment initiation; at 1-year follow-up, "seizure-free, with normal EEG findings," plus new self-feeding, eye contact, and independent sitting. - Koch et al. 2017 Patient F1:II.3: no further seizures over 7 months' follow-up; improved fine motor, cognition, language, and social-emotional development; blood morphology normalized within 12 weeks. - Koch et al. 2017 Patient F2:II.2: transitioned from a bedridden, minimally conscious state to communicative, with Coma Recovery Scale improving from 5 to 16 within 2 months and EEG normalization. - Sibling study (PMC7951104): early-treated sister (uridine started at age 5) achieved "resolution of generalized tonic-clonic seizures, improved absence seizures, normalized motor development, improved cognition and language...stabilized cerebellar atrophy" over 3 years, whereas her brother, treated much later (age 14), had only modest seizure-frequency reduction (5–10/day to 0–3/day) and remained nonverbal/care-dependent — underscoring the treatment-timing effect described in Section 8.

Advanced Therapeutics, Surgical, and Other Modalities

Gene therapy, cell therapy, RNA-based therapy, targeted molecular therapy, immunotherapy: None reported or applicable for DEE50 — the disease is managed via direct metabolic substrate replacement rather than genetic or immune-modulatory approaches.
Surgical intervention: Not disease-specific, though in refractory pre-diagnosis cases aggressive standard epilepsy interventions have been used, including pentobarbital-induced coma and epilepsy surgery (temporal lobe resection) in the severely affected, later-diagnosed brother in the sibling case report — interventions that preceded the eventual CAD diagnosis and uridine treatment.
Supportive/rehabilitative care: Standard antiepileptic drug (AED) management is used prior to/alongside diagnosis (with generally limited efficacy against the refractory seizures, consistent with 64% of epilepsy cases being drug-refractory); physical/occupational/speech therapy would be expected to support developmental gains, though not specifically quantified in the sources reviewed.

Experimental / Investigational

No CAD deficiency-specific registered clinical trials (ClinicalTrials.gov NCT identifiers) were identified in the sources reviewed; management is guided by an accumulating case-report/case-series evidence base rather than randomized trial data, consistent with the disease's ultra-rare status. (Uridine triacetate/Vistogard itself is FDA-approved for an unrelated indication — 5-FU/capecitabine overdose — and is being repurposed off-label for CAD deficiency based on the case-report evidence above.)

Treatment Strategy

Given the excellent safety profile of uridine and the demonstrated risk of untreated mortality, the literature explicitly recommends an empiric/pre-emptive treatment strategy: "uridine treatment should be attempted in patients who show signs of early developmental delay and refractory epilepsy" even before genetic confirmation is complete (PMC10921618) — an unusual and notable "treat first, confirm later" recommendation for a genetic disease, justified by uridine's low risk-to-benefit ratio and the steep cost of diagnostic/treatment delay documented in the sibling comparison.

Source: PMC10921618, Koch et al. 2017 (PMID 28007989), "Tale of Two Siblings" PMC7951104, Treatable ID App review

13. Prevention

Prevention Levels

Primary prevention: Not applicable in the vaccination/exposure-avoidance sense, since DEE50 is a fully genetic condition; the closest analog is reproductive genetic counseling for known carrier couples (see below) and, prospectively, newborn/expanded genetic screening to enable pre-symptomatic or early-symptomatic treatment initiation before irreversible neurological injury occurs.
Secondary prevention: Early recognition and rapid initiation of uridine therapy functions as the disease's central "secondary prevention" lever — converting a potentially fatal, progressively disabling disease into a largely controllable one. This is the single most emphasized preventive theme across the literature reviewed.
Tertiary prevention: Standard supportive management of complications (seizure emergency protocols for status epilepticus, nutritional/feeding support for dysphagia-related aspiration risk, developmental/rehabilitative therapies) in patients with residual disability.

Screening and Early Detection

Population-based screening: CAD deficiency is not currently included in standard newborn screening panels, but multiple authors explicitly call for its addition given the availability of an effective, low-toxicity treatment (PMC10921618: "CAD should be considered to be included in neonatal genetic screening").
Genetic/carrier screening: In families with a known proband, carrier testing of parents and cascade/prenatal testing of subsequent pregnancies is standard reproductive-genetics practice for autosomal recessive disorders, though this was not separately detailed as CAD-specific guidance in the sources reviewed.
Risk stratification: Consanguinity and known population founder alleles (e.g., Serbian Roma p.Met33Arg) are practical risk-stratification cues that should raise clinical suspicion in a child presenting with the developmental delay + refractory epilepsy + anemia triad.

Behavioral Interventions / Public Health / Environmental Interventions

Not applicable — DEE50 has no behavioral, lifestyle, or environmental risk-modification component; prevention is entirely genetics- and treatment-timing-driven.

Counseling

Genetic counseling for parents of an affected child (recurrence risk 25% per pregnancy for two carrier parents) is standard practice for an autosomal recessive disorder, and is implicit in the family-based diagnostic workups reported (e.g., trio WES with parental carrier confirmation in the Iranian case series, PMC8915536).

Prophylaxis

There is no described "prophylactic" pre-symptomatic use of uridine in genetically confirmed but pre-symptomatic siblings in the literature reviewed, though the strong treatment-timing effect documented in Section 8/11 provides a rationale for considering early/pre-symptomatic treatment in a molecularly confirmed younger sibling of an affected proband.

Source: PMC10921618, Treatable ID App review

14. Other Species / Natural Disease

Taxonomy and Natural Disease

A naturally occurring CAD deficiency has been reported in the domestic cat, specifically the Bengal breed — described as "the first report of a naturally occurring CAD deficiency in animals" (PMC12008240, 2025).

Species/breed: Felis catus, Bengal breed (NCBI Taxon: 9685 for Felis catus; a Vertebrate Breed Ontology [VBO] identifier for "Bengal" would apply, specific VBO ID not confirmed in sources reviewed).
Clinical presentation: A 4-month-old kitten developed "clusters of generalized tonic seizures with orofacial involvement and abnormal behavior" beginning at 13 weeks of age, with behavioral abnormalities and mild anisocytosis — closely paralleling human DEE50's seizure and hematologic phenotype. The kitten showed only partial response to conventional antiepileptic drugs (phenobarbital, levetiracetam), again mirroring the drug-refractory nature of human disease.
Genetic variant: A novel homozygous missense variant, p.Ser2015Asn, in the feline CAD gene, shown functionally to disrupt oligomerization of the C-terminal aspartate transcarbamylase (ATCase) domain. Genotyping of 110 unaffected Bengal cats identified 4 additional heterozygous carriers, indicating the variant segregates within the breed — a candidate breed-founder allele analogous to the human Roma founder mutation.
Outcome/treatment: The affected kitten was euthanized before uridine treatment could be trialed, so direct therapeutic proof-of-concept in the feline model is not yet available; however, given the mechanistic parallel to human disease, the authors suggest uridine supplementation "could benefit affected cats."
Significance as a model: The authors propose that CAD-deficient Bengal cats might serve as a spontaneous, naturally occurring large-animal model for studying DEE50 pathogenesis and testing uridine (or other) therapeutic strategies — a valuable complement to the case-report-driven human evidence base, since no engineered rodent/zebrafish/Drosophila CAD-deficiency model was identified in the literature reviewed.

Comparative Biology

CAD and its pyrimidine-biosynthesis function are highly evolutionarily conserved across eukaryotes (the trifunctional CAD gene arrangement itself arose from fusion of ancestral prokaryotic pyrimidine-pathway genes), supporting mechanistic conservation between the feline and human disease phenotypes. No zoonotic or cross-species transmission is relevant, as this is a non-infectious, purely genetic/metabolic disorder.

Model Organism Databases

Given the extreme rarity of the human disease and the very recent (2025) description of the only known natural animal model, no entries were identified in MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, or similar engineered-model-organism databases specifically for CAD-deficiency disease models; the Bengal cat represents a spontaneous veterinary case rather than a laboratory-engineered model.

Source: "Epileptic encephalopathy in a young Bengal cat caused by CAD deficiency," PMC12008240, dvm360 summary

15. Model Organisms

Naturally occurring (spontaneous) model: The Bengal cat described in Section 14 is, per current literature, the only reported animal model of CAD deficiency — a naturally occurring, non-engineered model arising from a breed-associated founder variant.
Engineered models (mouse, zebrafish, Drosophila, C. elegans, yeast): No CAD-knockout, knock-in, transgenic, or conditional engineered animal model specific to DEE50/CAD deficiency was identified in the sources searched. This is notable given CAD's fundamental, universally essential role in pyrimidine biosynthesis — a complete CAD-null mutation would likely be embryonic lethal in most model systems (consistent with the human disease's biallelic-hypomorphic/partial-loss-of-function requirement for survival), which may explain why viable engineered whole-organism models have not been reported; conditional/tissue-specific knockouts would be a logical unmet research need.
Cellular/in vitro models: The primary "model system" used across the literature is patient-derived dermal fibroblast culture, used to (a) directly demonstrate depletion of UTP/CTP/UDP-sugar pools, (b) demonstrate rescue of these metabolites by exogenous uridine in vitro, and (c) functionally classify novel CAD variants for pathogenicity and predicted uridine-responsiveness (the "Cell-based analysis of CAD variants" platform, Genetics in Medicine). No iPSC-derived neuronal or organoid model of CAD deficiency was identified in the sources reviewed.
Model limitations: Fibroblast-based assays capture the core biochemical lesion (pyrimidine/UDP-sugar depletion and its uridine-rescue) but cannot recapitulate neuronal-specific phenotypes (seizures, developmental regression, brain atrophy) or hematologic phenotypes (dyserythropoiesis), which is the translational gap the Bengal cat model is positioned to fill going forward.
Research applications: The fibroblast platform is used for (i) variant pathogenicity/functional classification and (ii) pre-clinical proof-of-concept for uridine (and potentially alternative pyrimidine-repletion strategies); the Bengal cat model is positioned for in vivo mechanistic and therapeutic (uridine efficacy/dosing) studies not achievable in cell culture.

Source: Genetics in Medicine — cell-based CAD variant analysis, "Epileptic encephalopathy in a young Bengal cat caused by CAD deficiency," PMC12008240

Summary of Key Ontology Term Suggestions for KB Population

Category	Term
Disease (MONDO)	MONDO:0014647
Disease (OMIM)	#616457
Disease (Orphanet)	ORPHA448010
Causal gene	hgnc:1424 (CAD)
Inheritance	HP:0000007 (Autosomal recessive inheritance)
Key phenotypes (HP)	HP:0011344 (developmental regression), HP:0011451 (drug-resistant epilepsy), HP:0002133 (status epilepticus), HP:0001903 (anemia), HP:0011273 (anisopoikilocytosis), HP:0001251 (ataxia), HP:0003132 (orotic aciduria), HP:0002015 (dysphagia)
Biological process (GO)	GO:0006207 ('de novo' pyrimidine nucleobase biosynthetic process)
Molecular function (GO)	GO:0004070 (aspartate carbamoyltransferase activity), GO:0004087 (carbamoyl-phosphate synthase activity), GO:0004151 (dihydroorotase activity)
Cell types (CL)	CL:0000540 (neuron), CL:0000764 (erythroid lineage cell)
Anatomy (UBERON)	UBERON:0000955 (brain), UBERON:0002037 (cerebellum), UBERON:0002371 (bone marrow)
Treatment agent (CHEBI)	CHEBI:46211 (uridine)
Treatment action (NCIT)	NCIT:C15986 (Pharmacotherapy)
Model organism (NCBITaxon)	NCBITaxon:9685 (Felis catus)

Sources

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	9
Resolved	9
Unresolved (possible confabulation)	0
Unverifiable	0
Quoted claims checked	9
Quoted claims found in source	5
Quoted claims not found in source	4
References weighed for topical relevance	9
On topic	9
Off topic	0

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

3 of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

PMC:PMC10921618 (abstract only): "gradually progressed after 3.5 years of age"
closest text in source: "Among them, 90% had onset before 3 years of age, with average of 1.6±1.8 years old"
PMC:PMC10921618 (abstract only): "impair[ing] axon and dendrite formation and lead[ing] to neuronal migration disorders"
Text part not found as substring: 'impair axon and dendrite formation and lead to neuronal migration disorders' (note: only abstract available for PMID:38454370, full text may contain this excerpt)
PMC:PMC7951104: "Tale of Two Siblings"
Text part not found as substring: 'Tale of Two Siblings'
PMC:PMC10921618 (abstract only): "CAD should be considered to be included in neonatal genetic screening"
closest text in source: "BACKGROUND: Developmental and epileptic encephalopathy-50 (DEE-50) is a rare clinical condition believed to be caused by a mutation in the CAD gene and is associated with a bleak prognosis"

Ask OpenScientist

OpenScientist Report

Classifications

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Progression

Prevalence

Differential Diagnoses

Experimental Models

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Developmental and Epileptic Encephalopathy 50 (DEE50 / CAD Deficiency): Comprehensive Research Report

1. Disease Information

2. Etiology

Disease Causal Factors

Risk Factors

Protective Factors

Gene-Environment Interactions

3. Phenotypes

Neurological / Developmental

Hematological

Other systemic/metabolic phenotypes (from MedGen clinical synopsis)

Neuroimaging (a semi-quantitative/imaging phenotype)

Quality-of-life impact

4. Genetic / Molecular Information

Causal Gene

Pathogenic Variants

Modifier Genes

Epigenetic Information

Chromosomal Abnormalities

5. Environmental Information

6. Mechanism / Pathophysiology

Molecular Pathway

Causal Chain (Upstream → Downstream)

Cellular Processes Involved

Protein Dysfunction

Metabolic Changes

Immune System Involvement

Tissue Damage Mechanisms

Molecular Profiling

7. Anatomical Structures Affected

Organ Level

Tissue and Cell Level

Subcellular Level

Localization

8. Temporal Development

Onset

Progression

Patterns

9. Inheritance and Population

Epidemiology

Inheritance Pattern (for the genetic etiology)

Population Demographics

10. Diagnostics

Clinical Tests

Genetic Testing

Omics-Based Diagnostics

Clinical Criteria

Screening

11. Outcome / Prognosis

Survival and Mortality

Morbidity and Function

Disease Course

Prediction

12. Treatment

Pharmacotherapy — Uridine Supplementation (the primary/definitive treatment)

Treatment Outcomes (pooled data, PMC10921618, n=18 treated patients)

Advanced Therapeutics, Surgical, and Other Modalities

Experimental / Investigational

Treatment Strategy

13. Prevention